Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
CONFIDENTIALITY STATEMENT 
All information concerning the Inv estigational Medicinal Product, s upplied by Neuren Pharmaceuticals 
Ltd. in connection with this study and not previously published, is considered c onfidential and proprietary 
information. This information incl udes the Investigator’s Brochure, Clinical Protocol, and Case Report 
Forms. This confidential information shall remain the sole property of Neuren Pharmaceuticals Ltd. and 
shall not be disclosed to others without prior written consent from Neuren Pharmaceuticals Ltd. and shall 
not be used except in the performance of this study. 
 The information developed during the conduct of the clinical study is also considered confidential and 
will be used by Neuren Pharmaceuticals Ltd. in co nnection with the developmen t of the Investigational 
Medicinal Product. This information may be disclose d as deemed necessary by Neuren Pharmaceuticals 
Ltd.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
TABLE OF CONTENTS 
CONFIDENTIALITY STATEMENT .....................................................................................................  2 
1. LIST OF ABBREVIATIONS ......................................................................................................... .... 7 
2. PROTOCOL APPROVAL ............................................................................................................... 11  
3. PROTOCOL SYNOPSIS ............................................................................................................. ..... 13  
4. SCHEDULE OF ASSESSMENTS ................................................................................................... 27  
5. INTRODUCTION .................................................................................................................. ........... 36  
5.1 Pitt-Hopkins Syndrome ......................................................................................................... ...... 36  
5.2 Current Treatments for Pitt-Hopkins Syndrome ......................................................................... 37  
5.3 Genetic Basis of Pitt-Hopkins Syndrome ................................................................................... 37  
5.4 Scientific Rationale for use of NNZ-2591 in Pitt-Hopkins Syndrome ....................................... 38  
5.5 Preclinical Data .............................................................................................................. ............. 38  
5.5.1  Overview of Pharmacology and Toxicology Findings ......................................................... 38  
5.5.2  Overview of Pitt-Hopkins Mouse Model Findings .............................................................. 39  
5.6 Clinical Data ................................................................................................................. .............. 40  
6. STUDY RATIONALE AND OBJECTIVES .................................................................................. 41  
6.1 Study Rationale ............................................................................................................... ............ 41  
6.2 Rationale for Dose Selection and Route of Administration ........................................................ 41  
6.2.0  Rationale for Dose Selection ................................................................................................ 4 1 
6.2.1  Rationale for Duration of Dosing ......................................................................................... 42  
6.2.2  Rationale for Selection of Efficacy Outcomes ..................................................................... 42  
6.3 Study Objectives and Endpoints ................................................................................................ . 43 
6.3.1  Primary Objective ............................................................................................................. .... 43  
6.3.2  Secondary Objectives .......................................................................................................... . 44 
7. STUDY DE SIGN .................................................................................................................. ............. 46 
7.1 Study Design Overview ......................................................................................................... ..... 46  
7.1.1  Study Design  
.................................................................................................................. ...... 47  
7.2 Dose-levels and Titration ..................................................................................................... ....... 47  
7.2.1  Adjustment of the Dose for Tolerability ............................................................................... 47  
7.2.2  Dose Escalation Review by the DSMC ................................................................................ 48  
7.3 Treatment Assignment .......................................................................................................... ...... 48  
7.4 Study Timeline ................................................................................................................ ............ 49  
7.5 COVID-19 .................................................................................................................................. 49  
8. PARTICIPANT POPULATION ...................................................................................................... 4 9 
8.1 Inclusion Criteria ............................................................................................................ ............ 50  
8.2 Exclusion Criteria ............................................................................................................ ........... 50  
8.3 Abnormal Laboratory Findings ..................................................................................................  54 
8.4 Withdrawal Criteria ........................................................................................................... ......... 54  
8.5 Risks and Benefits ............................................................................................................ .......... 54  
9. STUDY PROCEDURES .............................................................................................................. ..... 55  
9.1 Overview of Study Visits ...................................................................................................... ...... 55  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
9.2 Study Procedures by Visit ........................................................................................................... 56  
9.2.1  Visit 1 Screening/Baseline (in-clinic) – Week -4 ( r 2 days) ................................................ 56  
9.2.2  Visit 2 Screening/Baseline (telemedicine and in-home) – 2 Weeks from 
Visit 1 (± 1 day) ............................................................................................................. ....... 57  
9.2.3  Visit 3 Baseline (in-clinic) – Week 0 ( r 2 days) .................................................................. 58  
9.2.4  Visit 4 Treatment Period (telemedicine and in-home) – Week 1 ( r 1 day) .......................... 59  
9.2.5  Visit 5 Treatment Period (in-clinic) – Week 2 ( r 2 days) .................................................... 60  
9.2.6  Visit 6 Treatment Period (in-home nurse) – Week 3 ( r1 day) ............................................. 61  
9.2.7  Visit 7 Treatment Period (telemedicine and in-home) – Week 4 ( r1 day) ........................... 61  
9.2.8  Visit 8 Treatment Period (in-home nurse) – Week 5 ( r1 day) ............................................. 62  
9.2.9  Visit 9 Treatment Period (in-clinic) – Week 6 ( r 2 days) .................................................... 63  
9.2.10  Visit 10 Treatment Period (in-home nurse) – Week 7 ( r1 day) .......................................... 63  
9.2.11  Visit 11 Treatment Period (telemed icine and in-home) – Week 8 ( r 1 day) ........................ 64  
9.2.12  Visit 12 Treatment Period (in-home nurse) – Week 9 ( r 1 day) .......................................... 65  
9.2.13  Visit 13 Treatment Period (telemed icine and in-home) – Week 10 ( r1 day) ....................... 65  
9.2.14  Visit 14 Treatment Period – (in-home nurse) Week 11 ( r1 day) ......................................... 66  
9.2.15  Visit 15 Treatment Period (in-home nurse) – Week 12 ( rday) ......................................... 67  
9.2.16  Visit 16 End of Treatment (in-c linic) – Week 13 (-3 days) .................................................. 67  
9.2.17  Visit 17 Follow-up (telemedicine and in -home) – Week 15 (+ 4 days) ............................... 68  
9.3 Screening and Baseline Procedures ............................................................................................ 6 9 
9.4 Treatment of Participants ..................................................................................................... ....... 71  
9.4.1  Investigational Medicinal Product
 ........................................................................................ 71  
9.4.2  Investigational Medicinal Product Administration ............................................................... 71  
9.4.3  Treatment Compliance ......................................................................................................... 72 
9.4.4  Protocol Deviations ........................................................................................................... ... 72  
9.4.5  Early Discontinuation ......................................................................................................... .. 72 
9.4.6  Concomitant Therapy ...........................................................................................................  74 
9.5 Assessments ................................................................................................................... ............. 75  
9.5.1  Vital Signs ................................................................................................................... ......... 75  
9.5.2  Laboratory Tests ................................................................................................................... 76  
9.5.3  Blood sample for biomarkers and stool sample for microbiome .......................................... 80  
9.5.4  Medical/Clinical History ...................................................................................................... 81  
9.5.5  Physical and Neurological Exam .......................................................................................... 81  
9.5.6  81 
9.5.7  Ophthalmology Assessment ................................................................................................. 81  
9.5.8  12-lead ECG and Stopping Criteria for Prolonged QT ........................................................ 82  
9.5.9  Battery of Pitt-Hopkins Syndro me Assessment Instruments ................................................ 83  
9.5.10  Caregiver Diary ............................................................................................................... ..... 88  
9.6 Pharmacokinetic Measurements ................................................................................................. 88 
10. ADVE RSE EVENTS ................................................................................................................ ......... 90  
10.1  Definition of Adverse Event ................................................................................................... .... 90  
10.2  Definition of Serious Adverse Event .......................................................................................... 90 
10.3   
............................................................................................ . 91 

Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
10.4  Adverse Reactions ............................................................................................................. ......... 91  
10.5  Clinical Laboratory Abnormalities and Other Abnormal Assessments as AEs 
and SAEs ...................................................................................................................... .............. 91  
10.6  Time Period, Frequency, and Method  of Detecting AEs and SAEs ........................................... 91  
10.7  Recording of AEs and SAEs ..................................................................................................... .. 92 
10.8  Evaluating AEs and SAEs ....................................................................................................... ... 92  
10.8.1  Assessment of Intensity ....................................................................................................... . 92 
10.8.2  Assessment of Causality .......................................................................................................  92 
10.8.3  Follow-up of AEs and SAEs ................................................................................................ 93  
10.9  Prompt Reporting of the SAEs to the Sponsor ........................................................................... 94  
10.9.0  Completion and transmission of the SAE reports ................................................................. 94  
10.10  Deaths ........................................................................................................................ ................. 95  
10.11   ........................................ 95  
10.12  Pregnancy ..................................................................................................................... .............. 96  
11. STATISTICAL PLAN .............................................................................................................. ........ 96  
11.0  Definitions ................................................................................................................... ............... 96  
11.0.0  Participant Populations ....................................................................................................... .. 96 
11.1  Sample Size Determination ..................................................................................................... ... 97  
11.2  Safety Analyses................................................................................................................ ........... 97  
11.3  Efficacy Analysis ............................................................................................................. ........... 97  
11.4  Pharmacokinetic Analysis ...................................................................................................... ..... 98  
11.5  Biomarkers and Microbiome ..................................................................................................... . 98 
12. STUDY DRUG MANAGEMENT .................................................................................................... 98
 
12.0  Identity of Investigational Medicinal Product ............................................................................ 98  
12.1  Management of Clinical Supplies ...............................................................................................  99 
12.1. 0 Drug Accountability ........................................................................................................... .. 99 
12.2  Overdose ...................................................................................................................... ............... 99  
13. QUALITY ASSURANCE AND DATA MANAGEMENT .......................................................... 100  
13.1  Data Quality Assurance ........................................................................................................ .... 100  
13.2  Case Report Forms.............................................................................................................. ...... 100  
13.3  Monitoring .................................................................................................................... ............ 100  
13.4  Auditing ...................................................................................................................... .............. 101  
13.5  Source Documents .............................................................................................................. ...... 101  
13.6  Protocol Deviations ........................................................................................................... ........ 101  
13.7  Records Retention ............................................................................................................. ........ 101  
14. ETHICS ........................................................................................................................ .................... 103  
14.1  Informed Consent .............................................................................................................. ....... 103  
14.2  Institutional Review Board Approval ....................................................................................... 103  
14.3  Additional Protections for Minors ............................................................................................ 104 
15. STUDY MANAGEMENT ..............................................................................................................  105 
15.1  Principal Investigators ....................................................................................................... ....... 105  
15.2  Data Safety Monitoring Committee .......................................................................................... 105  
15.3  Publications .................................................................................................................. ............. 105  

Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
16. REFERENCES .................................................................................................................... ............ 106  
APPENDIX A.  ALLOMETRIC SCALING TO DETERMINE PHASE 2 
EXPOSURES ..................................................................................................................... .............. 109  
 
  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
1. LIST OF ABBREVIATIONS 
2MWT 2-Minute Walk test 
AAC Augmentative and alternative communication 
ABC-2 Aberrant Behavior Checklist 2 
AE Adverse event 
  
ALP Alkaline phosphatase 
ALT Alanine amino transferase 
AMSE Autism Mental Status Exam 
APTT Activated Partial Thromboplastin 
AS Angelman syndrome 
ASD Autism Spectrum Disorder 
AST Aspartate transaminase 
AUC Area under (concentration-time) curve to last time point 
AUC inf Area under (concentration-time) curve from time zero extrapolated to infinite time 
AUC 0-24 Area under (concentration-time) curve from time 0 to 24 hours at steady state 
AUC tau AUC from time zero to the end of the dosing interval 
bHLH Basic helix–loop–helix 
BID Twice daily 
BP 
BPI-SF Blood pressure Behavior Problems Inventory-Short Form 
bpm Beats per minute 
BR Bilirubin 
BSID-4 Bayley Scales of Infant Development version 4 
BUN Blood urea nitrogen 
CAS Chemical Abstracts Service 
CBC Complete Blood Count 
CBD Cannabidiol 
CDKL5 Cyclin-dependent kinase-like 5 
CdLS Cornelia de Lange syndrome 
CFR Code of Federal Regulations 
CGI-I Clinical Global Impr ession Scale – Improvement 
CGI-S Clinical Global Impression – Severity 
cGP Cyclic Glycine-Proline 
  
CLss/F Apparent total body clearance after oral administration  
CL
tv True population value for clearance of the drug 
Cmax The maximum observed blood concentration 
CMP Comprehensive metabolic panel 
CoRDS Coordination of Rare Diseases 
COVID-19 Coronavirus disease 2019 
CSHQ Child Sleep Habits Questionnaire 

Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Css Concentration at steady-state  
Ct Concentration at the last measurable time point 
Ctv True population value for clearance of the drug 
CĲ Concentration at the end of the dosing interval 
°C Degree(s) centigrade 
CVA  Costovertebral angle tenderness 
DBP Diastolic blood pressure 
dL Deciliter DNA Deoxyribonucleic acid DSM-5 Diagnostic and Statistical Manual of Mental Disorders, 5th Edition DSMC Data Safety Monitoring Committee DQ Development quotient EC Expressive communication ECG Electrocardiogram eCRF Electronic case report form EDC Electronic Data Capture System eGFR Estimated glomerular filtration rate EL Expressive language EOT End of Treatment FDA Food and Drug Administration FM Fine motor FR Fluid reasoning FSIQ Full scale intellectual quotient  g Gram GCP Good clinical practice GERD Gastroesophageal reflux disease GGT Gamma-glutamyl transferase GI Gastrointestinal GIHQ Gastrointestinal Health Questionnaire GM Gross motor GMP Good manufacturing practice GRAS Generally Recognized as Safe GSV Growth scale values Hb Hemoglobin HbA1C Glycated (or glycosylated) hemoglobin Hct Hematocrit HDPE High-density polyethylene hr, hrs Hour, hours HPF High power field HTN Hypertension IB Investigator’s brochure ICH International Counc il on Harmonisation 
ICMJE International Committee of Medical Journal Editors ICND Impact of Childhood Neurological Disability Scale 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
IGF-1 Insulin-Like Growth Factor 1 
IND Investigational new drug 
IMP Investigational medicinal product 
IQ Intelligence quotient 
IRB Institutional review board 
ITT Intent to treat 
IUD Intrauterine device 
  
kg  Kilogram 
KN Knowledge 
L Liter m  Meter 
MAO Monoamine oxidase 
MB-CDI MacArthur-Bates Communi cative Development Inventory 
MCH Mean cell hemoglobin 
MCHC Mean cell hemoglobin concentration 
MCV Mean cell volume 
MDMA Methylenedioxymethamphetamine 
MedDRA Medical Dictionary of Regulatory Activities mg Milligram MIS-C Multisystem Inflammatory Syndrome in Children 
mL Milliliter mmHG Millimeter of mercury 
mmol/L Millimole per liter 
ms Millisecond N Number of participants 
NCA Non-compartmental analysis 
NDD Neurodevelopmental disorder 
NGAL Neutrophil gelatinase-associated lipocalin 
NHANES National Health and Nutrition Examination Survey NOAEL No adverse effect level 
NVIQ Nonverbal IQ 
ORCA Observer-Reported Communication Ability 
OTC Over-the-counter PHRF Pitt Hopkins Research Foundation 
PK Pharmacokinetic PLT Platelets PMS Phelan-McDermid syndrome 
popPK Population pharmacokinetics 
PP Per protocol 
PTHS Pitt-Hopkins syndrome 
QI-Disability Quality of Life Inventory-Disability 
QR Quantitative reasoning 
QTcF Fridericia’s correction factor for QT 

Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
 
  RBC Red blood cell count 
RDW, RDW 
CV Red cell distribution width 
RL Receptive language 
rpm Respirations per minute 
SAE Serious adverse event 
SAER Serious adverse event report 
SAP Statistical analysis plan 
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 
SB5 Stanford-Binet Intelligence Scales version 5 
SBP Systolic blood pressure 
SCQ Social Communication Questionnaire 
SUSAR Suspected Unexpected Serious Adverse Events 
t1/2 Terminal elimination half-life 
T3 Triiodothyronine 
T4 Thyroxine 
TCF4 Transcription Factor 4 
TEAE Treatment emergent adverse event THC Tetrahydr ocannabinol 
T
max Time to maximal concentration 
TSH Thyroid stimulating hormone 
UA Urinalysis UK United Kingdom 
ULN Upper limit of normal 
US United States 
VIQ Verbal intelligence quotient 
VR Visual reception 
VS Visual-spatial 
WBC White blood cell count 
WM Working memory 
WT
centered Population value for the weight in the adult population corresponding to the derived 
CL TV 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
3. PROTOCOL SYNOPSIS 
Protocol Neu-2591-PTHS-001 Phase 2: Pediatric Safety, Tolerability, and Pharmacokinetic Study  
Study Protocol Title An Open-Label Study of the Safety, Tolerability, and 
Pharmacokinetics of Oral NNZ-2591 in Pitt-Hopkins Syndrome 
Sponsor Neuren Pharmaceuticals Limited 
Investigational Product  Research Number NNZ-2591 
Generic Name Cyclo-L-Glycyl -2-Allyl Proline (cG -2-AllylP) 
Protocol Number Neu-2591-PTHS-001 
NCT Number [STUDY_ID_REMOVED] 
IND Number 155461  
Clinical Phase (Trial Type) Phase 2  
Treatment Indication Pitt-Hopkins syndrome (PTHS) 
Primary Objective x To investigate the safety, tolerability, and pharmacokinetics 
(PK) of treatment with NNZ-2591 Oral Solution, 50mg/mL 
Investigational Medicinal Product (IMP) in children and 
adolescents with PTHS 
Secondary Objectives x To investigate measures of ef ficacy during treatment with 
NNZ-2591 Oral Solution, 50 mg/mL IMP in children and 
adolescents with PTHS 
Trial Design Neu-2591-PTHS-001 is an open-label study of the safety, tolerability, 
and PK of NNZ-2591 Oral Solution, 50mg/mL in male and female 
children and adolescents with PTHS. Participants receive treatment of 
orally administered NNZ-2591 for a total of 13 weeks. 
 Overall Design 
There are a total of 17 study visits over the duration of the study, 5 in-clinic visits, and 12 remote/in-home vi sits (see Table 1). Remote visits 
between the Investigator or designee at the clinical site and the participant at home are conducted via telemedicine or video facilities 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Protocol Neu-2591-PTHS-001 Phase 2: Pediatric Safety, Tolerability, and Pharmacokinetic Study  
as appropriate. In-home visit refers to a visit made to the participant’s 
home by a visiting nurse. 
The study will commence with an approximately 4 to 6 week 
Screening and Baseline period. Duri ng this Screening/Baseline period, 
participants will be assessed for study eligibility. Rescreening of 
participants is allowable under cert ain circumstances with the approval 
of the Sponsor and Medical Monitor.   During the Screening/Baseline period  data will also be collected to 
establish the participant’s baseline characteristics and symptom severity based on assessments collect ed during the 4 to 6 week period. 
There are two in-clinic visits and one remote/in-home visit during the 
Screening and Baseline period (Visits 1, 2, 3).   Once eligibility is confirmed, participants will be dosed at a starting 
dose of 4 mg/kg twice-daily (BID) and up-titrated to a target dose of 
12 mg/kg BID of orally administered NNZ-2591. The mg/kg dosing is based on the participant’s weight at Baseline (Visit 3). Participants will 
receive treatment with NNZ-2591 for a total of 13 weeks. During the 
treatment period there are three in-clin ic visits: Week 2 (Visit 5), Week 
6 (Visit 9) and Week 13 (Visit 16). There is a remote visit by the Investigator via telemedicine and a same-day in-home visit by a 
visiting nurse at Week 1, Week 4, Week 8, and Week 10. Additionally, 
there are in-home visits by a visiting nurse at Week 3, Week 5, Week 
7, Week 9, Week 11, and Week 12. 
All participants will have a combined remote Follow-Up visit with the 
Investigator via telemedicine and an in-person home visit by a visiting 
nurse approximately 2 weeks after the end of treatment (Week 15, 
Visit 17).  For all visits designated as in-clinic, an in-person visit is preferred. All 
requests for off-site assessments due to extenuating circumstances, such as related to the Coronavi rus-disease (COVID-19) health 
emergency, must be approved by th e Sponsor or Medical Monitor in 
advance.  
Enrollment Groups 
For enrollment, the participants will be divided into three groups by 
age: 13–17-year-olds (Group 1), 8–12-year-olds (Group 2), and 3–7-
year-olds (Group 3). Enrollment will commence in the oldest age 
group (Group 1). After at least th ree participants in Group 1 have 
received two weeks of treatment with the IMP at the starting dose (4 mg/kg BID), safety and tolerability da ta will be reviewed by the Data 
Safety Monitoring Committee (DSMC). If tolerability and safety data 
are deemed acceptable, enrollment for Group 2 will proceed and 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Protocol Neu-2591-PTHS-001 Phase 2: Pediatric Safety, Tolerability, and Pharmacokinetic Study  
dosing will begin at the starting dose. When at least three participants 
in Group 2 have received the first two weeks of treatment at the 
starting dose, safety and tolerability data will be reviewed by the DSMC. If tolerability and safety  data for Group 2 are deemed 
acceptable, enrollment for Group 3 will commence and dosing will 
begin at the starting dose. 
 
COVID-19  As a result of the COVID-19 public health emergency, this protocol 
includes provision for alternative methods of performing safety and 
efficacy assessments in accordance with the FDA Guidance on 
Conduct of Clinical Trials of Me dical Products during the COVID-19 
Public Health Emergency January 27, 2021.* Provision is made for 
off-site assessments where necessary, and all efforts have been made to 
ensure the alternative processes are co nsistent as much as possible with 
in-clinic visits. For visits that are designated as in-clinic, an actual in-
clinic visit is preferred. However, an in-home/remote visit may be conducted for a scheduled in-clinic vi sit with the prior approval of the 
Sponsor and Medical Monitor. Clinical investigators are to document the reason for any contingency meas ures implemented. If at any time 
in the study, the participant or hi s or her caregiver tests positive for 
VHYHUH DFXWH UHVSLUDWRU\ V\Q GURPH FRURQDYLUXV 6$56 -CoV-2) or 
becomes ill with symptoms of C OVID-19, the family should be 
instructed to contact the site as so on as possible. Once informed, the 
Investigator should contact the Medical Monitor. 
Study Population Approximately 10-20 male and female participants between the ages of 
3 and 17 years are anticipated  to complete the study.  
The participants will be categorized  by age in three groups: 13 to 17-
year-olds (Group 1), 8 to 12-year-olds (Group 2), and 3 to 7-year-olds (Group 3). Enrollment will be balanced to the extent possible by sex and age with a minimum of 3 males and 3 females across all age groups, and a minimum of 3 participants in each age group. 
Inclusion Criteria To be eligible for this study, partic ipants must meet all of the inclusion 
criteria and none of the exclusion criteria. Inclusion criteria include: 
1. Clinical diagnosis of PTHS with a documented disease-causing genetic etiology for the disorder.  
2. Males or females ages 3 to 17 years at screening, inclusive. 
 
* FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health 
Emergency: Guidance for Industry, Investigators, and Institutional Review Boards (Center for Biologics 
Evaluation and Research; Center for Devices and Radi ological Health; Center for Drug Evaluation and 
Research; Office of the Commissioner; Of fice of Clinical Policy and Programs ; Office of Clinical Policy; Office 
of Good Clinical Practice) (2021). 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Protocol Neu-2591-PTHS-001 Phase 2: Pediatric Safety, Tolerability, and Pharmacokinetic Study  
3. Body weight of 12 kg or highe r at Screening. Weight 
measurements may be repeated during the Screening period in 
consultation with the Medical Monitor. 
4. Participants with a Clinical Global Impression – Severity 
(CGI-S) score of 4 or greater at the Screening visit. 
5. Not actively undergoing regression or loss of skills, defined as 
no persistent loss of previously  acquired developmental skills 
for a period within 3 months of the Screening visit. 
a. Previously acquired skills include any skill established 
and used on a daily basis for at least 3 months. 
b. Variations in use of skills that is part of a general 
pattern of ups and downs , as determined by the 
investigator, are not counted as regression. 
c. Skills may include language, non-verbal 
communication, fine motor skills, ambulation (including gait, coordination, independence of 
walking/standing), social skills, play, self-help.  
6. Each participant must be able to swallow the IMP provided as 
a liquid solution. 
7. The participant’s caregiver(s) mu st have sufficient English 
language skills to complete care giver assessments in English. 
Exclusion Criteria To be eligible for this study, partic ipants must meet all of the inclusion 
criteria and none of the exclusion criteria. Exclusion criteria include: 
Laboratory and Screening Values  
1. Body weight < 12 kg at Screeni ng. Weight measurements may 
be repeated during the Screening period in consultation with 
the Medical Monitor. 
2. HbA1c values above 7% at the Screening visit. 
3. Clinically significant abnormalities (as determined by the 
Investigator) in safety laboratory values, or vital signs, as 
measured at the Screening visit. Laboratory testing may be repeated during the Screening pe riod in consultation with the 
Medical Monitor. 
4. Positive pregnancy test at the Screening visit. 
5. QTcF Exclusions (any of the following): 
a. Screening QTcF interval of >450 ms assessed using Fridericia’s correction factor based on 12-lead electrocardiogram (ECG) obtained as a continuous ECG of at least 50 seconds. 
b. Hypokalemia (Serum potassium at the Screening visit 
<3.0 mmol/L or mEq/L). Serum potassium may be 
repeated during the Screening period with the agreement of the Medical Monitor. 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Protocol Neu-2591-PTHS-001 Phase 2: Pediatric Safety, Tolerability, and Pharmacokinetic Study  
35. Seizure medication whose dosing regimen is not stable 8 
weeks prior to commencing IMP. Adjustments for changes in weight or age are allowable. If the treatment was discontinued, the discontinuation must have o ccurred no fewer than 2 weeks 
before the Screening visit. 
36. Psychotropic medications or a ny other medication used for a 
chronic illness (not including antibiotics, pain relievers, anti-
diarrheals, and laxatives) w hose doses and dosing regimen 
have not been stable for at least 4 weeks prior to the Screening visit. If the treatment was discontinued, the discontinuation must have occurred no fewer than 2 weeks before the 
Screening visit. 
a. This includes nutraceutical treatments and 
cannabinoids (tetrahydroc annabinol [THC] and 
cannabidiol [CBD]) which are allowable but also must 
meet the stability conditions above. 
b. Pain relievers, laxatives, and anti-diarrheals may be 
used as needed. 
c. Standard of care immuni zations and vaccinations 
(including COVID-19) are allowed and are not subject to the above stability conditions. 
d. The Investigator should consult with the medical 
monitor if a participant is being treated with ocular 
toxic, hepatotoxic, nephrotoxic or antibiotic 
medications.  
e. If the Investigator is unsure if a medication is 
permitted, the Medical Monitor should confirm if the 
medication is allowed and will provide written 
documentation to support the use of the medication, if allowed. 
 Regression of Skills  
37. Actively undergoing regression or loss of skills defined as a 
persistent loss of previously  acquired developmental skills 
within 3 months of the Screening visit.  
a. Previously acquired skills include any skill established and used on a daily basis for at least 3 months. 
b. Variations in use of skills that is part of a general pattern of ups and downs  (as determined by the 
Investigator) are not counted as regression. 
c. Skills may include language, non-verbal communication, fine motor skills, ambulation 
(including gait, coordination, independence of 
walking/standing), social skills, play, self-help.  
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Seizures 
 38. Seizure profile that is not stable 8 weeks prior to commencing IMP. The overall pattern of seizure activity for the participant 
should be consistent with their typical pattern of seizures and 
be stable within the 8-week period in terms of type, intensity, duration, and frequency as de termined by the clinical 
Investigator.  
 Medical Conditions  
39. Currently pregnant, lactating or breastfeeding. 
40. Current clinically significant (as determined by the Investigator) cardiovascular, gastrointestinal, respiratory, or endocrine disease or clinically significant organ impairment. The Investigator may consult with the Medical Monitor as 
needed if he/she is uncertain if symptoms are exclusionary. 
41. Current clinically significant (as determined by the 
Investigator) hypo- or hyperthyroidism. If the participant has hypo- or hyperthyroidism that is controlled with medication, the Investigator should consult with the Medical Monitor to 
confirm if the participant is eligible.  
42. Type 1 or Type 2 diabetes me llitus requiring insulin (whether 
well controlled or uncontrolled),  or uncontrolled Type 1 or 
Type 2 diabetes.  
43. Has planned surgery during the study. 
44. History of, or current, cerebrovascular disease or brain 
trauma. 
45. History of, or current catatonia or catatonia-like symptoms. 
46. History of, or current, malignancy. 
47. Current major or persistent depressive disorder (including bipolar depression). 
48. Significant uncorrected hearing impairment. 
 Other Criteria 49. Allergy to strawberry. 
50. The participant is unable to take the IMP orally and swallow 
the IMP provided as a liquid solution. Administration of the 
IMP by nasogastric tube, feeding tube, thickened liquid, or 
gastrostomy tube is not allowed. 
51. Has participated in another inte rventional clinical study within 
30 days prior to the Screening visit.  
52. Prior enrollment in this clinical trial.  
a. Individuals who leave the study during the Screening period and have not entered the study may be able to 
rescreen pending review a nd approval of the Sponsor 
and Medical Monitor.  
b. Individuals who were deemed eligible and entered the 
study (enrolled) who discontinue the study may not re-
enroll in the study.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Protocol Neu-2591-PTHS-001 Phase 2: Pediatric Safety, Tolerability, and Pharmacokinetic Study  
53. The participant is judged by the Investigator or the Medical 
Monitor to be inappropriate for the study for any reason.  
Investigational Product NNZ-2591 Oral Solution, 50mg/mL will be administered open-label at 
the target dose of 12 mg/kg BID. The mg/kg dosing is based on the 
participant’s weight at Baseline (Visit 3). Participants will be up-titrated as outlined in the table below.  
Dosing Schedule 
 
Week 1 
and 
Week 2 Week 3 Week 4 
and 
Week 5 Week 6 Week 7 
and 
Week 8 Week 9 Week 10 
to Week 
13 
4 mg/kg 
BID  
(8 mg/kg 
daily) 4 mg/kg BID  
(8 mg/kg 
daily)
1 8 mg/kg BID  
(16 
mg/kg 
daily) 8 mg/kg 
BID  
(16 
mg/kg 
daily)
1 12 
mg/kg 
BID  
(24 
mg/kg 
daily) 12 mg/kg 
BID  
(24 
mg/kg 
daily)  12 mg/kg 
BID  
(24 
mg/kg 
daily)  
DSMC 
Reviews 
Data 
Prior To 
Up-
titration
2 DSMC 
Reviews 
Data 
Prior To 
Up-
titration
2 DSMC 
Reviews 
Data 
After 2 
Weeks 
on 12 
mg/kg 
to 
Confirm 
Safet y2 
BID = twice daily; DSMC = Data Safety Monitoring Committee 
1Participants will stay on their current dos e until the data is reviewed by the DSMC. 
2Expected time for DSMC review will be one week. 
The dose titration schedule ma y be modified based on updated 
pharmacokinetic modelling analyses including data from the study. 
 
The IMP will be administered at a starting dose of 4 mg/kg BID for a total of approximately three weeks. After two weeks of dosing at the staring dose, the data will be reviewed by the DSMC, and the participants will stay on the starting dose while the data are reviewed.  
If safety and tolerability are deemed  acceptable, participants will be 
up-titrated to 8 mg/kg BID and be do sed for a total of approximately 
three additional weeks. After two weeks of dosing at 8 mg/kg, the data 
will be reviewed by the DSMC, and the participants will stay on the 8 mg/kg dose while the data are review ed. If safety and tolerability are 
deemed acceptable, participants w ill be up-titrated to12 mg/kg BID 
and remain on this dose for seven we eks, The DSMC will determine if 
dose escalation can proceed based on pre-specified stopping rules detailed in the body of the protocol. The total administration period for 
NNZ-2591 will be 13 weeks.  For staggered enrollment, the 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Protocol Neu-2591-PTHS-001 Phase 2: Pediatric Safety, Tolerability, and Pharmacokinetic Study  
participants will be divided into th ree groups by age: 13 to 17-year-
olds (Group 1), 8 to 12-year-olds (Group 2), and 3 to 7-year-olds 
(Group 3). The DSMC will review and approve the start of enrollment in the younger age groups.  
NNZ-2591 is provided as a ready-to-use  strawberry flavored liquid for 
oral administration. The IMP should not be mixed with water, liquid 
thickeners, or food for administration. The dose can be taken from a cup or dosing syringe. Doses should be given on an empty stomach (2 
hours after the previous meal or snack and 30 minutes prior to the next). 
 
The first dose of IMP will be administered in the clinic after all 
Baseline assessments are completed, or, if the Investigator judges that it is too late in the day, on the following day. The participant should be monitored for at least three hours after the first dose. If the first dose is 
administered the day following Baseline, vital signs should be 
collected before the dose is administered. Day 1 of dosing is defined by the date when the first dose is taken. At this visit, the site will provide IMP for the caregiver to dispense at home. Enough IMP will 
be provided to cover the interval un til the next in-clinic visit when the 
caregiver will be re-supplied from the site. 
 The protocol includes procedures for dose titration and dose adjustments, if any are necessary (Section 7.2), and pre-specified 
stopping criteria (i.e., discontinuation of IMP) consistent with the exclusion criteria, including QT cF, renal, ocular, and hepatic, 
exclusion criteria (Section 9.4.5 ). 
Endpoints Primary Endpoints 
 
Safety: 
The incidence of AEs and SAEs from commencement of IMP 
administration through to the time of the last study visit will be 
evaluated. Vital signs, laboratory  measures, urine output history, 
physical exam results (neurological, ophthalmologic, and general), 
, and ECGs will also be evaluated from 
screening/baseline through the end of the study.  Tolerability will be assessed base d on caregiver reports and the 
Caregiver Diary, required dosing adjustments or discontinuations, 
dosing compliance, and AEs relate d to participant experience. 
 
Pharmacokinetics: 
Pharmacokinetic blood samples will be  collected according to the age 
appropriate sampling schedule for each participant (See Table 2 and 
Table 3 ). Pharmacokinetic concentratio ns and exposure parameters for 
NNZ-2591 will be derived by spar se non-compartmental analysis 

Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Protocol Neu-2591-PTHS-001 Phase 2: Pediatric Safety, Tolerability, and Pharmacokinetic Study  
(NCA), and may include maximum concentration (C max), area under 
the concentration-time curve from time 0 to the end of the dosing 
period (AUC tau) and other parameters. 
 
Efficacy: 
x Overall Improvement:  
o PTHS-specific Clinical Global Impression Scale–Improvement (CGI-I), Overall Improvement Scores; clinician-assessed 
o PTHS-specific Clinical Global  Impression Scale – Domain 
Improvement Scores; clinician-assessed 
o Caregiver Global Impression Change Scores; caregiver-
assessed 
x PTHS Symptom Severity : 
o PTHS-specific Clinical Global Impression Scale–Severity (CGI-S)–Overall; clinician-assessed 
o PTHS-specific Clinical Global Impression Scale–Severity (CGI-S)– Domain; clinician-assessed 
o Caregiver Top 3 Concerns Like rt Scale Scores; caregiver-
assessed 
x Communication :  
o MacArthur-Bates Communicativ e Development Inventory 
(MB-CDI); caregiver-assessed 
o Observer-Reported Communication Ability Measure 
(ORCA); caregiver-assessed 
x Maladaptive Behavior :  
o Aberrant Behavior Checklist-2; caregiver-assessed  
o Behavioral Problems Inventory-Short Form (BPI-SF); 
caregiver-assessed 
x Sleep: Child Sleep Habits Questionnaire (CSHQ) Scores; 
caregiver-assessed 
x GI: Gastrointestinal Health Qu estionnaire (GIHQ); caregiver-
assessed  
x Adaptive Behavior : Vineland Adaptive Behavior Scales-3, 
Comprehensive Interview version; clinician-assessed 
x Motor:  
o Bayley Scales of Infant Development 4 (BSID-4) motor 
scale, clinician-assessed (for participants who are assessed on the BSID-4) 
o Modified two-minute walk test; clinician-assessed 
x Quality of Life (Child and Caregiver) 
o Quality of Life Inventory-Disability (QI-Disability); 
caregiver-assessed 
o Impact of Childhood Neurological Disability (ICND)-
Overall quality of life rating; caregiver-assessed  
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Protocol Neu-2591-PTHS-001 Phase 2: Pediatric Safety, Tolerability, and Pharmacokinetic Study  
Biomarkers and Microbiome Samples 
Blood and stool samples will be collected for analysis of biomarkers 
and gut microbiome. The analysis will be detailed in a separate analysis plan but will not include DNA sequencing. Samples will be 
collected at Screening (Visit 1), Ba seline (Visit 3, before dosing) and 
at the End of Treatment (EOT) visit, or upon early termination. 
 
Sample Size Estimation Sample sizes were estimated for this open-label study using within-
participant change as the measure of improvement. Given the limited 
data from interventional trials in th ese patient populations, and that this 
is the first clinical study of NNZ-2591 IMP in this population, 
treatment change estimates were ba sed on CGI-I data from completed 
clinical trials in other rare, neurod evelopmental disorders. Based on the 
information provided in Glaze et al. 2019 (Double-blind, randomized, 
placebo-controlled study of trofinetide in pediatric Rett syndrome), the standard deviation of the CGI-I is approximately 0.7 at a single timepoint.
1 For a sample size of 10 participants, a two-sided 
significance level of 0.05, and a Wilcoxon signed-rank test, the study will be able to detect a difference of  0.87 units of change in the CGI-I 
at a power of 0.90. For a power of 0.80, 0.85, and 0.90, the detectable difference would be 0.75, 0.80, and 0.87 or larger, respectively. The effect size for a power of 0.80, 0. 85, and 0.90 is 1.07, 1.14, and 1.24, 
respectively. If the observed standard  deviation is larger, the detectable 
differences would also be larger. For example, if the standard deviation 
is 1.5, the detectable difference for a power of 0.80, 0.85, and 0.90 is 
1.61, 1.71, and 1.86 or larger, respectively. For a sample size of 20 participants, a two-sided significan ce level of 0.05, and a Wilcoxon 
signed-rank test, the study will be able to detect a difference of 0.55 units of change in the CGI-I at a power of 0.90. For a power of 0.80, 0.85, and 0.90, the detectable difference would be 0.48, 0.51, and 0.55 or larger, respectively. 
Statistical Methods Safety  
Adverse events and other safety data will be summarized as 
frequencies and percentages, desc ribed in terms of severity and 
potential attribution. Objective safe ty assessments will be summarized 
over time on study; shift tables at  time points of interest may be 
generated.  Details of the safety an alyses will be specified in the SAP. 
 
Efficacy 
Efficacy will be assessed by lookin g at within-participant changes 
from the Baseline period to the EOT. The participant’s baseline 
characteristics and symptom sever ity will be established based on 
assessments collected during the 4 to 6 week Screening/Baseline 
period. Baseline values will be based on  the average values of visits 1, 
2, and3 for assessments collected at  more than one visit. A Wilcoxon 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
Protocol Neu-2591-PTHS-001 Phase 2: Pediatric Safety, Tolerability, and Pharmacokinetic Study  
signed rank test will be used to test for improvement and a significance 
level will be computed.   Potentially influential factors will be  considered and addressed with a 
linear regression model. This mode l may include covariates such as 
age, sex, NVIQ or NVIQ equivalent, genotype, history of regression (yes/no), ASD diagnosis yes/no with no more than two covariates included in any model. Descripti ve statistics and corresponding 
graphics will be used to present the results. The efficacy analysis details will be specified in the SAP.  
Pharmacokinetics: 
NNZ-2591 PK concentrations will be listed by participant and time 
point for each dose level with ac tual time they were acquired. The 
concentrations will be summarized by time, dose level and age group. 
For the concentrations measured at trough points dose, relationship 
will be examined statistically with  age group and/or body weight of 
participant as covariate. 
Overall exposure parameters for NNZ-2591 such as C max and AUC tau 
may be derived by sparse non-comp artmental analysis (NCA). 
Additionally, PK concentrations of NNZ-2591 measured in pediatric 
participants will be used to refi ne a population PK model developed 
from adult NNZ-2591 PK data and extrapolated to the pediatric 
population. After refinement, complete profiles for each participant will be simulated using range of va riability of model parameters and 
individual covariate effects. A standard NCA approach will be used for simulated profiles to calculate parameters C
max, AUC tau, etc. for 
characterization of NNZ-2591 exposu re in pediatric participants. 
The PK analysis details will be specified in the PK Statistical Analysis Plan (PK SAP).  Biomarkers and Microbiome: Biomarker analysis will be detaile d in the SAP and will not include 
DNA sequencing.  
Microbiome analysis will be described in a separate analysis plan. 
Trial Sites Approximately 4-7 sites in the US. 
Neuren Pharmaceuticals Ltd. Clini cal Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
diary must be completed daily during the entire Screening/Baseline period whether it is 4 weeks or 6 weeks. The Screening visit  (Visit 1) and 
Baseline visit (Visit 3) may be conducted over three consecutive da ys. It is preferrable that ECGs, safety labs and biomarker s ample collection are 
conducted on the same day. All assessments must be completed within the window for th e visit (visit day ± 2 days).  For Visit 3 , all assessments 
must be completed before administration of the IMP. 
 
b The End of Treatment visit is conducted wh en the participant is still on IMP treatment.  For early termination, in addition to study completers, 
participants who have received IM P for longer than 2 weeks and discontinue premat urely any time after Visit 5 should return to the investigational 
site for final safety and efficacy assessments as scheduled for the EOT visit (Visit 16) and complete the study exit form. 
c At Visit 3, the first dose of IMP will be administered in the clinic after all Baseline assessments are completed, or, if the Investigator judges that 
it is too late in the day, on the following day. The participan t should be monitored for at least three hours post first dose. If the first dose is 
administered the day following Baseline, vita l signs (except height) should be collecte d before the dose is administered. Day 1  of dosing is defined 
by the date when the first dose is taken. At the Baseline visit, the site will dispen se an adequate supply of IMP for dispensin g by the caregiver at 
home. Dosing at the end of Baseline counts as Day 1 whether one or  two doses are given. Dosing may not exceed 91 days including Day 1, and all 
efficacy assessments for the EOT visit must be  completed on or before Day 91 of treatment. 
 
d A clinic visit is preferred but an off-site visit may be condu cted for a scheduled in-clinic vi sit in extenuating circumstance s due to the COVID-19 
health crisis. All requests for off-site vi sit assessments due to extenuating circumstances must be approved in advance by the Sponsor or Medical 
Monitor. The in-clinic visits may be conducted over three cons ecutive days. All assessments including caregiver-completed asses sments must be 
done within the window for the visit. 
e This is a combined remote and in-person nurse visit. The remote visit is conducted by the site via telemedicine or video facil ities as appropriate. 
Any caregiver-completed assessments should be completed the same day of the visit or no earlier than the day before the visit ( except the 
Caregiver Diary which is completed daily) and reviewed by the In vestigator. A modified version of the physical and neurological  exam will be 
done at the remote visits based on the guidance documents provided to the Investigator. At the W eek 4, the site should confirm with the caregiver 
that the child has started the new dose if they were approved for dose titration. These combination remote/in-home visits will be conducted 
simultaneously whenever possible, or they will ideally be conducte d on the same day. If that is not possible, the telemedicine visit and the nurse 
visit may be conducted over two consecutive da ys. A combined remote visit may be c onducted in-clinic by the study staff if agre ed upon by the 
Investigator and the caregiver.See Section 9.1 and Section 9.2. 
 
f In-home visits will be conducted by a vis iting nurse. At every nurse visit, the nurse will collect urine, vital signs including  weight, and blood 
samples for a comprehensive metabolic panel (CMP). The nurse will also conduct a targeted physical exam assessing general appea rance, 
abdominal/CVA tenderness, and edema. A supra pubic exam (bladder palpation) to assess for urinary retention may be performed. The visiting 
nurse will also review the dosing diary, query oral intake, and do a review of tolera bility. Blood samples for CBC with differe ntial, and 
coagulation will be collected at Weeks 4, 8, 10 and Week 15 (indicated by “N” in the Schedule of Assessments). At the post-trea tment follow-up 
visit at Week 15, the visiting nurse will also collect ECG, in ad dition to the above assessments.  At Week 7, the site will also  have a phone call with 
the caregiver to confirm that the child has started the new dose if they were appr oved for dose titration. The site will confir m the visiting nurse has 
Neuren Pharmaceuticals Ltd. Clini cal Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
been informed so the dosing schedule can be reviewed with the family during the in-home visit. A nurse-only in-home visit may b e conducted in-
clinic by the study staff if agreed upon by th e Investigator and the caregiver. See Section 9.1and 9.2. 
 
g  The in-clinic physical exam will include an abdominal exam and an assessment of CVA. A suprapubic exam (bladder palpation) to a ssess for 
urinary retention may be performed.  Genera l awareness will be captured as part of the neurological exam. For in-home nursing visits, the nurse 
will do a Targeted Physical exam assessing general appearance (e.g., alertness), an abdominal/CVA, and edema. A suprapubic exam  (bladder 
palpation) to assess for urinar y retention may be performed.  
 
h A modified version of the neurological and physical exam will be done for the remote visit based on the guidance documents provided to the 
Investigator.  
 
 
j The visiting nurse will query any changes in tolerability during the in-home visit. Any changes will be noted and provided to the Investigator. The 
Investigator will also query changes in tolerability and note any changes in the remote  assessment. The Investigator is respons ible for determining 
and reporting any changes that  qualify as Adverse Events. 
 
k The caregiver fills out the diary daily from the first day of screening through two weeks after the EOT Visit. X denotes revie w of the Caregiver 
Diary including the daily summary log, medication log, non-medicina l treatments log, seizure log and new/changes in symptoms lo g. All visits: 
The Investigator (or appropriately credentia led designee) is responsible for reviewing for ALL visits. In-home visits: At the i n-home nurse visit, 
the nurse will review the Caregiver Diary to  flag and check any issues that could be  reported as AEs. The nurse will notify the  site about any 
urgent issues the day of the visit and note anything else in th e source documents. The nurse does not sign the diary. The sourc e documents and the 
diary will be sent to the site. The Investigator (or appropriat ely credentialed designee) will review the diary and source docu ments collected at the 
in-home visit. 
Note: There are two rows for Caregiver Diary review procedures (to emphasize the importance of thorough and complete dosing 
documentation): this row (Caregiver Diary)  denotes that the caregiver fills out the diary daily and a designated clinician revi ews it for 
safety/tolerability; a second row (Review dos ing compliance documentation in diary, see footnote “l”) is intended to ensure tha t the 
caregiver is administering IMP/documenti ng dose properly in the Caregiver Diary. 
 
l The daily dosing log in the Caregiver Diar y will be reviewed at all post-baseline vis its through EOT. If any doses are missed or mis-dosed, this 
should be queried with the caregiver and a ppropriate feedback given to the family. Th is feedback should be documented in the so urce documents.  
At the in-home nurse visit, the nurse will re view the caregiver diary to check any issu es and provide feedback to the family at the visit. The nurse 
will notify the site about any urgent issues the day of the vis it and note anything else in the source documents. The nurse does not sign the daily 
dosing log/summary page. The source documents and the diary will be sent to the site. The Investigator (or appropriately credentialed delegee) 
will review the diary and source documents collected at the in-home visit. 
 
m Coagulation includes prothrombin time, activated partial thro mboplastin (aPTT), and international normalized ratio (INR). 

Neuren Pharmaceuticals Ltd. Clini cal Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
 
n A Comprehensive Metabolic Panel will be assess ed every post-enrollment visit (see Section 9.5.2 ). If abnormal findings are observed on renal or 
liver function tests, additional tests as is clinically indicated may be conducted as described in Sections 9.5.2.1 and 9.5.2.3). 
 
o Both urinalysis and a urine screen for drugs of abuse will be evaluated at  Screening (See Section 9.5.2). 
 
p For female participants who have reached menarche. 
 
q See Table 2 and Table 3 fo r PK blood collection times. 
 
r The Bayley is done for participants who ca nnot attain a basal score on SB 5 or for whom the SB5 is developmentally inappropriate . 
 
s The study exit form should also be completed if  the participant termin ates the study early. 
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 34 of 112 Table 2  Pharmacokinetic Blood Sampling Schedule (Participants Ages 7 to 17 Years Old) 
Week  Visit No.  Treatment  Timing of Sample  
(relative to start of dosing)a Sample Time  
Point  
2 5   Pre dose (-120 to -15 minutes)b 1 
      1-3 hours post dosec 2 
   4-7 hours post dosec 3 
6 9 Mid-treatment Pre dose (-120 to -15 minutes) b 4 
     1-3 hours post dosec 5 
     4-7 hours post dosec 6 
13 16 End of Treatment  Pre dose (-120 to -15 minutes)b 7 
      1-3 hours post dosec 8 
      4-7 hours post dosec 9 
a All post-dose windows are determined from the first dose of the visit (morning dose) and all PK samples must be 
collected before the second dose (PM dose).   
 
 b Pre dose counts as both T0 and 12 hours post dose from  previous evening (near trough). The previous evening’s 
dose should be taken in the evening as late as possible, preferably before bedtime. 
 
c Post-dose sample collection can be +/- 15 minutes of the target time and must be at least 30 minutes from the 
previous sample (samples can be no closer than 30 minu tes apart). The actual collection time must be recorded. 
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 35 of 112 Table 3  Pharmacokinetic Blood Sampling Sc hedule (Subects Ages 3 to <7 Years Old) 
Week  Visit No.  Treatment Collection 
Window Timing of Sample  
(relative to start of dosing)a Sample Time  
Point  Comment 
2 5   
   Pre dose (-120 to -15 
minutes)b 1  
     A 1-3 hour post dosec 2  Sample 2 can be taken at 
either collection window 
A or Bd    OR OR 
   B 4-7 hours post dosec 
6 9 Mid-treatment  Pre dose (-120 to -15 
minutes) b 3  
     A 1-3 hours post dosec 4 Sample 4 can be taken at 
either collection window 
A or Bd    OR OR 
     B 4-7 hours post dosec 
13 16 End of Treatment  Pre dose (-120 to -15 
minutes)b 5  
     A 1-3 hours post dosec 6 Sample 6 can be taken at 
either collection window 
A or Bd    OR OR 
     B 4-7 hours post dosec 
a All post-dose windows are determined from the first dose of the visit (morning dose) and all PK samples must be 
collected before the second dose (PM dose).   
 
 b Pre dose counts as both T0 and 12 hours post dose from  previous evening (near trough). The previous evening’s 
dose should be taken in the evening as late as possible, preferably before bedtime. 
 
c Post-dose sample collection can be +/- 15 minutes of the target time and must be at least 30 minutes from the 
previous sample (samples can be no closer than 30 minu tes apart). The actual collection time must be recorded. 
 
d For the 3 to <7 year-old age range, two sampling timepoints are taken at each visit. The post-dose sample may be 
taken at either collection window A or collection window B. Ideally, it is better that the second sample is not taken 
at the same collection window at each visit. So, an attempt should be made to vary the collection time of the second 
sample as is feasible. For example, if on visit 5 the second sample is taken in collection window B, at visit 9 or 16, 
the second sample should ideally be taken in collection window A.  
 
 
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 36 of 112  
5. INTRODUCTION 
5.1 Pitt-Hopkins Syndrome 
Pitt-Hopkins syndrome (PTHS) is a rare, neurodevelopmental disorder characterized by developmental 
delays, moderate to profound intellectual disab ility, absent/limited speech, distinctive facial 
dysmorphology, and breathing problems such as epis odic hyperventilation and/or breath-holding while 
awake. Other common symptoms may include repetitive behaviors and social communication 
impairments, constipation, severe near-sighted ness (myopia), sleep disturbances, and seizures.2, 3  
Individuals with PTHS have distinct facial features th at are important elements of the diagnostic criteria, 
including a square face with narrow forehead, thickened helix, wide nasal bridge, beaked nose 
characterized by down-turned nasal tip, flared nasal al ae and wide nasal tip, full cheeks, wide mouth, full 
lips and a cupid bow upper lip.3-7 Myopia is observed in the majority of patients (48-88%) and strabismus 
and astigmatism are also observed.4, 6-11  
Individuals with PTHS demonstrate severe developmen tal delay in motor milestones including delayed 
ambulation and delayed, or ultimately absent, speech.8 While moderate to prof ound intellectual disability 
has been reported across the literature, most individuals  have severe to profound cognitive impairments.  
Mental age equivalents for development level that ha ve been reported as betwee n 3.5 to 36 months for 
individuals between 32 m onths and 32 years old.9, 12 The majority of individuals (68%) have absent or 
limited speech (less than 5 words) and all have impaired speech.4, 6, 8, 9 While between 46-70% of 
individuals are reported to be independently ambulatory, the majority of individuals have gait 
abnormalities including a wide-based ataxic gait, as well as impaired motor coordination and hypotonia.4, 
6, 8-11, 13, 14 Adaptive function for individuals with PTHS is low with developmental equivalent scores of 20 
or less.12  
Breathing abnormalities are a characteristic feature and affect 45%-86% of individuals with PTHS, in 
particular hyperventilation or hyperven tilation with apnea (46%) when awake.3, 6-11, 15 GI problems are 
also highly prevalent, and can be severe, w ith around 35% needing corrective treatment.13 Chronic 
constipation, with an onset as early as infancy,8, 9 is particularly common (67%-85% of patients).6-11, 15  
Seizures present another challenge for 30%-51% of individuals with PTHS.4, 6, 8-11, 13, 15 The range of 
seizure types includes generalized tonic-clonic, atonic, focal onset, and infantile spasms.6, 8, 10, 16-18 
Additionally, between 18%-42%  of individuals with PTHS experience some type of sleep disturbance, 
typically insomnia or night awakenings.6, 8  
Individuals with PTHS face a range of behavioral challenges.3, 4, 6-8, 10 Compared to Angelman Syndrome 
(AS) and Cornelia de Lange syndrom e (CdLS), other genetically based disorders with similar early signs 
and features, the behavioral phenotype of PTHS is pa rticularly characterized by the following: 1) a high 
level of Autism Spectrum Disorder (ASD) symptoma tology 2) social communication difficulties, 3) 
atypical sensory processing, and 4) high levels of physical aggression and self-injury.13 Aggression and 
aggressive behavior are observed  in 40%-54% of individuals,8, 11-13 and in 38% of individuals, this has 
included destruction of property.13 Between 60-71% of individuals demo nstrate self-injurious behaviors.6, 
9, 11 Anxiety (81%) and agitation (88%) are also common symptoms.6 
Up to 95% of individuals met the cut off scor e for possible ASD on the Social Communication 
Questionnaire (SCQ) screener for ASD.13 Individuals have also been shown to score high on the Autism 
Diagnostic Interview measure.12 On the SCQ, they demonstrated more problems with communication and 
reciprocal social interaction than individuals with AS. They also showed lower sociability with both 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 37 of 112 familiar and unfamiliar people compared to individuals  with AS, and with familiar people compared to 
individuals with CdLS.13 Individuals with PTHS also have atypical sensory processing. In response to 
behaviors in social contexts, the majority of individuals are hyporesponsive, but are hyperresponsive to 
sensory input.13  
Stereotypic behaviors are highly prevalent (54%-94%)3, 6, 8, 10, 12, 13 and include object stereotypy,3, 13 body 
stereotypies such as body rocking (54%-78%) and hand and finger stereotypies (48-85%) including clapping, flapping (up to 80%), hand-wringing/hand- washing (45%), hand mouthing or biting (54%), 
finger movements (54%), and wrist movements (45%).
6-9, 12, 13 Head shaking and head banging have also 
been reported.6, 9  
5.2 Current Treatments for Pitt-Hopkins Syndrome 
No methods exist to prevent the onset of PTHS, nor is there any cure or approved medication for 
treatment for PTHS.  
Prescribed medications for individuals with PTHS are for the management of specific symptoms such as 
seizures or GI problems,3, 8 and do not address the unde rlying dysfunction of the disorder. GI problems of 
constipation and GERD are treated using standard treatments such as laxatives, stool softeners and protein 
pump inhibitors.3, 8 Seizures are commonly treated with standa rd antiepileptics such as valproic acid, 
levetiracetam, lamotrigine, and carbamazepine.3, 9, 19 There are no systematic recommendations for the use 
of psychotropic medications to treat behavioral pr oblems, but caregivers report using methylphenidate, 
clonidine and benzodiazepine for agitation/irritability and anti-psychotics for challenging behaviors.3, 8 
Mood-stabilizing medications and anti-epileptics have been used for treating breathing abnormalities,8 
and melatonin has been used for sleep issues.3, 8  
Non-medication strategies for the treatment of  PTHS are typically multimodal and require the 
involvement of multiple clinicians with diverse areas of expertise.2, 3 In centers that specialize in the 
treatment of individuals with PTHS, the standard of care includes physical, occupational, behavioral and 
speech therapies, as well as targeted approaches to orthopedic concerns and ga strointestinal dysfunction 
and seizures, as is reflected in recen tly published international guidelines.3 Establishment of an effective 
long-term care plan that can be implemented across settings, which includes pediatric medical follow-up 
and a transition plan for adult care, is a recommende d approach to the treatment of individuals with 
PTHS.2, 3, 20  
5.3 Genetic Basis of Pitt-Hopkins Syndrome 
Pitt-Hopkins syndrome is caused by loss of function of the transcription factor 4 ( TCF4 ) gene due to 
heterozygous hypomorphic or null mu tations, or up to 12 Mb interstitial deletions on chromosome 18q 
including the TCF4  gene, which result in TCF4  haploinsufficiency.3, 6, 10, 11, 14, 18, 21, 22 The majority of 
disease-causing genetic changes are de novo.2, 3, 11  
TCF4 is expressed in neurons and glial cells and it enc odes a basic helix–loop–helix (bHLH) transcription 
factor that is known to heterodimerize with several other bHLH transcription factors that play important roles in neurogenesis and neurona l migration in the brain, regula ting glial cell differentiation, and 
regulating immune cell function.
14   
TCF4  is highly expressed during embryoni c and early postnatal development18 and has particularly high 
expression in the hippocampus.23-25 It is also expressed in adult brain, lymphocytes, fibroblasts, gut, 
muscle, and myenteric plexus.18, 21, 26, 27  Recent cognitive and imaging studies have also shown that TCF4 
is important for normal brain function.25, 28  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 40 of 112 phenotype of fmr1 knockout mice and corrected impairment of AKT/ERK activation and abnormal 
dendritic morphology. 
A comprehensive battery of safety, pharmacology, and toxicology studies conducted in mice, rats and 
dogs has also been conducted, providing support for th e progression of the drug into a Phase 2 clinical 
trial in a pediatric population with PTHS. Summaries of these studies are presented in the NNZ-2591 IB.   
5.6 Clinical Data 
NNZ-2591 has been studied in 28 healthy male and female adult volunteers. Study Neu-2591-HV-001 
was a combined Phase 1 study, with an open-label single dose stage and a double-blind, randomized, 
multiple ascending dose-escalation stage with 12 particip ants enrolled in 2 open-la bel single-dose cohorts 
and 16 participants enrolled in 2 randomized, double-b lind, placebo-controlled multiple dose cohorts. The 
single ascending dose stage of the Phase 1 study eval uated doses of 12.5 mg/kg and 50 mg/kg. The two 
cohorts comprising the multiple asce nding dose stage of the Phase 1 study evaluated twice-daily dosing at 
3 mg/kg for 1 day followed by 6 mg/kg for 6 days (Cohort M1) and 6 mg/kg for 1 day, then 9 mg/kg for 
1 day followed by 12 mg/kg for 5 days (Cohort M2).   
 Twice daily dosing for 5 days at 12 mg/kg following up-titration for 1 day at 6 mg/kg and 1 day at 9 mg/kg was found to be safe and generally well-toler ated. There were no deaths , Serious Adverse Events 
(SAEs), or severe Treatment Emergent adverse events  (TEAEs) reported during the conduct of this study. 
All adverse events (AEs) were mild  or moderate. No clinically signi ficant laboratory, ocular, physical 
examination, vital sign, or cardiac abnormalities were reported. There was a single discontinuation due to 
moderate AEs of somnolence and ataxia after the administration of one dose. The participant’s two 
TEAEs resolved after treatment was withdrawn.  The most common TEAEs deemed related to drug we re a cluster of apparently related neurological 
symptoms that included somnolence/drowsiness, blurre d vision/difficulty focusing, ataxia/unsteady gait, 
dizziness, and vertigo. The majority of these TEAE s occurred within 2-3 hours of a participant’s first 
dose. All resolved spontaneously without requiring me dical intervention, most within 24 hours from 
onset. This pattern suggests that these TEAEs are an acute phenomenon temporally correlated with initial 
T
max rather than being associated with cumulative exposure and that participants possibly develop 
tolerance to these neurological Aes. There were no cl inically significant findings on the laboratory tests or 
electrocardiograms (ECGs), and no rena l or hepatic findings were observed. 
 PK appeared to be linear and predictable, w ith peak and total exposures (as measured by C
max and area 
under the plasma concentration-time curve [AUC], respec tively) appearing to increase in a generally dose 
proportional manner after both the morning and evening doses.  A summary of the study is provided in the NNZ-2591 IB.   
In addition to this study, NNZ-2591 is being assessed  in Phase 2 studies in Phelan McDermid syndrome, 
Angelman Syndrome, and Prader-Willi Syndrome. In these open label st udies participants receive BID 
treatment for a total of 13 weeks. The dose is up-titrated from 4 mg/kg (three weeks of treatment) to 8 mg/kg (three weeks of treatment) to 12 mg/kg (7 week s of treatment). As of the date of the last annual 
report to FDA, a total of 16 participants had been  dosed across this study, (PTHS-001) and the Angelman 
Syndrome and Phelan McDermid Syndrome studies. There were no SAEs or Adverse Events of Special 
Interest (renal, hepatic or ocular) report ed. There have been two discontinuations.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 41 of 112 6. STUDY RATIONALE AND OBJECTIVES 
6.1 Study Rationale 
Pitt-Hopkins syndrome (PTHS) is a rare genetic neurodevelopmental disorder caused by the loss of 
function of the TCF4  gene, and the resulting reduction in the number and morphology of dendritic spines 
and the synaptic plastic ity in mature neurons.29 Characterized by developmental delays, moderate to 
profound intellectual disability, absen t/limited speech, distinctive facial  dysmorphology, and breathing 
problems,2, 3 PTHS causes lifelong difficulties for the indi viduals affected by the condition and their 
families. There is currently no approved treatment for PTHS.  
In pre-clinical pharmacodynamic studies, NNZ-2591 h as demonstrated the ability to improve impaired 
synaptic structure and signaling as well as re scuing the neurobehavioral phenotype. NNZ-2591 is a 
synthetic analogue of cGP that inhibits neuroinfla mmation and restores synap tic function and plasticity. 
NNZ-2591 has better stability than cGP, readily crosses the blood-brain barrier and has high 
bioavailability when administered orally. Therefore, th e purpose of this study is to investigate the safety, 
tolerability, and pharmacokinetics (PK) of treatment with oral NNZ-2591 Oral Solution, 50 mg/mL IMP 
in children and adolescents with PTHS. 
6.2 Rationale for Dose Selection and Route of Administration 
6.2.0 Rationale for Dose Selection  
Selection of the dose schedule of NNZ-2591 IMP that will be utilized in this study is informed by: 
x Results of toxicity studies which assessed the effe cts of oral NNZ-2591 in dogs and juvenile rats 
with 13 weeks of dosing and a 4-week recovery period. These studies, summarized in the IB, 
found that the No Adverse Effect Level (NOA EL) of NNZ-2591 was 200 mg/kg/day in juvenile 
rats and 120 mg/kg/day in adul t dogs. At the NOAEL, no NNZ-2591-related clinical signs of 
toxicity considered adverse, or mortality occu rred and no non-reversible effects on the nervous 
system, skeletal system, renal or reproductive system were observed. 
x Pharmacodynamic studies in Tcf4+/- mice and wild-type, littermate controls found that 6 weeks of 
dosing at 100 mg/kg BID and 200 mg/kg BID we re effective in reversing cognitive and 
neurobehavioral deficits analogous to the human PTHS phenotype.     
x The safety, tolerability, and PK of NNZ-2591 Oral  Solution as determined by the First-in-Human 
(FIH) Phase 1 study. NNZ-2591 appeared to be  safe and generally well-tolerated when 
administered orally twice daily for 7 days at doses up to 12 mg/kg BID. There were no SAEs. All 
AEs were mild or moderate. There were no NNZ-2591 related abnorma l laboratory results, 
ECGs, or vital signs and no sentinel safety issues. This study is summarized in the IB. 
x The results of allometric scaling of exposure at steady state (AUC tau) in healthy, adult volunteers 
at 12 mg/kg indicate that exposures for the pediatric population at weights lower than 70 kg are estimated to be lower than those observed fo r the adult population in the Phase 1 study at 
12 mg/kg. Therefore, dosing all children at a maxi mum of 12 mg/kg BID will not put them at risk 
of exposures higher than that experienced by h ealthy adults. At the same time, the predicted 
exposures are expected to be in the range of what  was identified as a potentially efficacious dose 
from the animal models so there is a prospect of benefit with dosing at the maximum proposed dose of 12 mg/kg BID. A summary of the allo metric scaling analysis is presented in Appendix A .  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 42 of 112 x Data from a parallel PK study in the same background strain of mice utilized in the 
pharmacodynamic study was conducted to support comparison of exposure between mice and 
humans. This study, combined with PK data from the Phase 1 study, resulted in an estimate that a 
dose of approximately 10 mg/kg BID in adults should result in daily exposure equivalent to 
100 mg/kg BID in the mouse. The weight-based doses in the Phase 2 study are intended to result 
in a distribution of exposures equivalent to th e 12 mg/kg dose in adults that will provide a 
reasonable opportunity for efficacy as well as being predicted to be safe and well-tolerated. 
In this Phase 2 study, NNZ-2591 Oral Solution, 50 mg/mL will be administered orally BID over the 
course of 13 weeks. Participants will be up-titrated  according to the dosing schedule outlined in Section 
7.2. The dose titration schedule may be modified based  on updated PK modelling in cluding data from the 
study. 
6.2.1 Rationale for Duration of Dosing 
Given the overall safety and tolerability profile of NN Z-2591 in preclinical studies to date, 13 weeks of 
treatment at this dose is expected to be safe an d well-tolerated. NNZ-2591 has been shown to be well-
tolerated in animal studies for up to 13 weeks at up to 200 mg/kg/day for rats and 120 mg/kg/day for 
dogs. In addition, NNZ-2591 Oral Solution appears to  exhibit generally linear kinetics with no time-
dependent effect on PK parameters and no evidence of accumulation in humans.  
A study duration of 13 weeks is expected to provide su fficient time for changes in  synaptic plasticity to 
manifest in behavioral and symptom change. A number of functionally relevant symptoms in PTHS could 
show a more immediate response as a result of this change in synaptic  function. Based on findings in a 
parallel program of another IGF-1 metabolite analog (trofinetide) in Rett syndrome, it has been observed 
that improvements in some symptoms can be seen at 4 or 6 weeks of treatment.1, 32 This includes 
improvements in symptoms clinicians considered c linically meaningful such as behavior, seizures, 
ambulation, social interaction, motor skills (hand use) and repetitive behaviors. As such, there is a 
prospect of benefit with dosing at the maximum propo sed dose of 12 mg/kg BID for 7 weeks with a total 
duration of approximately 13 weeks of treat ment in this Phase 2 study in PTHS.  
Other symptoms or skills such as communication may n eed longer than 4 to 6 weeks to manifest, and the 
treatment period of 13 weeks in this study may allow sufficient time for possible change in more complex 
symptoms to manifest. So, on the whole, within a 13-week period it is possible for there to be a range of 
symptoms that could improve and be beneficial to patients. In sum, this approach to dosing maintains a 
balance between risk and benefit for this first Phase 2 study in the PTHS population. 
6.2.2 Rationale for Selection of Efficacy Outcomes 
Pitt-Hopkins syndrome is a severely limiting, lifelo ng disorder in which affected individuals cannot 
achieve the functional capacity to care for themselv es, protect themselves from harm, form normal peer 
relationships, or achieve independent  daily living skills. The constellation of symptoms in PTHS have 
significant impact on the functionality of affected indi viduals and their overall quality of life and well-
being. The debilitating impairments in cognition, language and social function hinder overall social, 
emotional, and academic developm ent and independent execution of tasks of daily living. Adaptive 
behavior is severely impaired with individuals remaining at low devel opmental and functional levels even 
as they age.12 This greatly limits their ability to have a ny independence in executing activities of daily 
living rendering them dependent on support throughout their lives. Their severe disability puts them at 
further risk of adverse medical, developmental, psychosocial, and family outcomes.8, 33  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 43 of 112 The underlying neuropathology and severe neurologica l and neurodevelopmental impairments also lead 
to neurobehavioral dysfunction and dysregulation wh ich substantially disrupt daily activities, put 
individuals at greater risk of harm, and can be pot entially life-threatening. Hyperventilation and apnea 
result in a number of negative impacts on h ealth including swollen abdomen, excessive burping, 
decreased oxygen saturation, changes in pallor , cyanosis, chronic hypoxia, and finger clubbing.6, 9, 10 
Seizures can be debilitating to co gnitive and neurological developmen t. Self-injurious behaviors put 
individuals with PTHS at risk of physical harm, potentially with long-term cumulative effects which 
decreases overall quality of life. There is current ly no on-going natural history study of PTHS. Cohort 
studies, and a recent consensus statem ent paper on diagnosis and treatment3 have provided detailed 
information characterizing the clinical manifestations of the disorder and their functional impact. This has 
provided insights on the symptoms that are central to the disorder and are important  to patient functioning 
and well-being. The Pitt Hopkins Research Foundation (P HRF) maintains a family registry as part of the 
Coordination of Rare Diseases (CoRDS) Registry at  Sanford which collects information on clinical 
symptoms (https://pitthopkins.org/r esearch/how-to-get-involved-in-research-today/family-registry/). The 
PHRF also did an assessment of the patient and family  experience by conducting a trend analysis of data 
shared through social networks.34 In this analysis they identified the most concerning symptoms, most 
common methods of disease management, and unmet needs.  
Together, the output from these initiatives and expert clinical advice has provided guidance into the 
important domain areas to address with NNZ-2591 treat ment that would be most relevant and potentially 
beneficial to patients with PTHS (see Section 9.5.9 ). The secondary outcome of efficacy in this study will 
be assessed by evaluating a range of  symptom areas to determine if th ere is preliminary evidence of 
efficacy, but also importantly to gather informa tion about the performance of outcome measures and the 
influence of baseline patient attributes on clinical response.  
6.3 Study Objectives and Endpoints 
6.3.1 Primary Objective 
To investigate the safety, tolerability, and PK of treatment with NNZ-2591 Oral Solution, 50 mg/mL in 
children and adolescents with PTHS.  
6.3.1.1  Primary Endpoints 
Safety: Incidence of AEs and SAEs from commenceme nt of IMP administration through to the time of 
the last study visit will be evaluated. Vital signs , laboratory measures, physical exam results 
(neurological, ophthalmologic, and general) urine output history, , and ECGs 
will also be evaluated from screening/b aseline through the end of the study.  
Tolerability: Tolerability will be asse ssed based on caregiver reports and the caregiver diary, required 
dosing adjustments or discontinuations, dosing compli ance and AEs related to participant experience. 
Pharmacokinetic:  
NNZ-2591 PK concentrations will be listed by participan t and time point for each dose level with actual 
time they were acquired. The concentrations will be summarized by time, dose level and age group. For 
the concentrations measured at trough points dose re lationship will be examin ed statistically with age 
group and/or body weight of participant as covariate. 
Overall exposure parameters for NNZ-2591 such as C max and AUC tau may be derived by sparse non-
compartmental analysis (NCA). Ad ditionally, PK concentrations of NNZ-2591 measured in pediatric 

Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 44 of 112 participants will be used to re fine a population PK model devel oped from adult NNZ-2591 PK data and 
extrapolated to pediatric population. After refineme nt, complete profiles for each participant will be 
simulated using a range of variability of model parameters and individual covariate effects. A standard 
NCA approach will be used for simulated profiles to calculate parameters C max, AUC tau, etc. for 
characterization of NNZ-2591 exposure in pediatric participants. 
6.3.2 Secondary Objectives 
To investigate measures of efficacy during treatment with NNZ-2591 Oral Solution, 50 mg/mL in children and adolescents with PTHS . 
 
6.3.2.1  Secondary Endpoints 
Within-participant changes will be assessed from th e Baseline period to End of Treatment (EOT) using 
the following measures: 
Overall Improvement: 
x PTHS-specific Clinical Global Impression Scale–Improvement (CGI-I) Overall Improvement 
Score; clinician-assessed  
x PTHS-specific Clinical Global Impression Scale–Domain Improvement Scores; clinician-
assessed 
x Caregiver Global Impression of Ch ange Scores; caregiver-assessed 
PTHS Symptom Severity: 
x Clinical Global Impression Scale–Severity (CGI-S)–Overall Severity Score; clinician-
assessed 
x Clinical Global Impression Scale–Severity (CGI-S)–Domain Scores; clinician-assessed  
x Caregiver Top 3 Concerns Likert Scale Scores; caregiver-assessed 
Communication 
x MacArthur-Bates Communicative Developmen t Inventory (MB-CDI) Scores; caregiver-
assessed 
x Observer-Reported Communication Ability Me asure (ORCA) Score; caregiver-assessed 
Maladaptive Behavior 
x Aberrant Behavior Checklist-2 (ABC-2) Scores; caregiver-assessed 
x Behavior Problem Inventory-Short Form  (BPI-SF) Scores; caregiver-assessed 
Sleep: Child Sleep Habits Questionnaire (CSHQ) Scores; caregiver-assessed  
GI: Gastrointestinal Health Questionnai re (GIHQ) Scores; caregiver-assessed 
Adaptive Behavior: Vineland Adaptive Beha vior Scales-3 Scores; clinician-assessed 
Motor 
o Bayley Scales of Infant Development 4 (BSI D-4) motor scale, clinician-assessed (for 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 45 of 112 participants who are assessed on the BSID-4) 
o Modified Two-minute Walk Test scores; clinician-assessed 
Quality of Life (Child and Caregiver) 
x Quality of Life Inventory-Disability (Q I-Disability) Scores; caregiver-assessed 
x Impact of Childhood Neurological Disability (ICND) Overall Quality of Life rating; 
caregiver-assessed  
6.3.2.2  Exploratory Endpoints 
Blood and stool samples will be collected for an explor atory analysis of biomarkers and gut microbiome. 
The analysis will be detailed in a separate analysis plan but will not incl ude DNA sequencing. Samples 
will be collected at Screening (Visit 1) and Baseline (V isit 3, before dosing) and at the EOT visit, or upon 
early termination. 
  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 46 of 112 7. STUDY DESIGN 
7.1 Study Design Overview 
This is a Phase 2, open-label study of the safety and tolerability of NNZ-2591 Oral Solution, 50 mg/mL in 
male and female children and adolescents with Pitt-H opkins syndrome. Approximate ly 10 to 20 male and 
female participants between the ages of 3 and 17 years will be enrolled and receive treatment of NNZ-
2591 Oral Solution, 50 mg/mL for a total of 13 weeks.  Additional participants may be screened, enrolled, 
and treated to achieve appr oximately 20 study completers. 
There will be a total of 17 study visits, comprising 5 in-clinic visits, and 12 re mote telemedicine/in-home 
nurse visits. The study will commence with an appr oximately 4 to 6 week Screening and Baseline period. 
During this Screening/Baseline period, participants w ill be assessed for study eligibility and data will be 
collected to establish the particip ant’s baseline characteristics and sy mptom severity using a variety of 
assessments (Section 9.2). Two in-clinic visits and one remote/in -home visit (Visits 1, 2, 3) comprise 
Screening and Baseline.  
 Once eligibility is confirmed, participants will receiv e the starting dose of 4 mg/kg and then be up-titrated 
to the target dose (see Section 7.2). Participants will receive treatment for a total of 13 weeks. During the 
treatment period, there are three in-clinic visits: Week 2 (Visit 5), Week 6 (Visit 9) and Week 13 (Visit 16). 
There is a combined remote, telemedicine visit by th e site investigator and an in-home visit by a visiting 
nurse for safety at Week 1 (Visit 4), Week 4 (Visit 7), Week 8 (Visit 11) and Week 10 (Visit 13). These 
combination remote/in-home visits w ill be conducted simultaneously when ever possible, or they will be 
conducted on the same day with the telemedicine visit occurring first. If it is not feasible to conduct these visits simultaneously or on the same day, the telemedi cine portion of the visit and the nurse portion of the 
visit must be conducted on two consecu tive days. In-home visits with a vis iting nurse will be done at Weeks 
3 (Visit 6), 5 (Visit 8), 7 (Visit 10), 9 (Vis it 12), 11 (Visit 14), and 12 (Visit 15). 
 All participants will also have a remote post-treatment  visit with the Investigator via telemedicine and an 
in-person home visit by a visiting nurse approximately 2 weeks after the end of treatment (Week 15, Visit 
17).  For all visits designated as in-clinic, an in-person visi t is preferred. Off-site assessments may be allowed 
due to extenuating circumstances, such as those rela ted to the COVID-19 health emergency. All requests 
for off-site assessments must be approved in  advance by the Sponsor or Medical Monitor. 
 Participants will be divided into three groups by age:  
x 13 to 17 years old (Group 1) 
x 8 to 12 years old (Group 2) 
x 3 to 7 years old (Group 3)  
Enrollment will commence with the oldest age group and will proceed as follows. After at least three 
participants in Group 1 have rece ived two weeks of treatment at th e starting dose, the Data Safety 
Monitoring Committee (DSMC) will review data on safety, and tolerability. If tolerability and safety for those participants during the specified period is deem ed acceptable, enrollment for Group 2 will proceed 
and dosing will begin at the starting dose. When at l east three participants in Group 2 have received the 
first two weeks of treatment, the DSMC will review data on safety, and tolerability. If tolerability and 
safety for Group 2 is deemed accepta ble, enrollment for Group 3 will co mmence and dosing will begin at 
the starting dose. 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0
Confidential Neu-2591-PTHS-001 October 30, 2023
Page 47 of 1127.1.1 Study Design 
Figure 1 Neu-2591-PTHS-001 Study Design Diagram    
7.2 Dose-levels and Titration
The total administration period for NNZ-2591 Oral Solution, 50 mg/mL IMP will be 13 weeks. As 
outlined below in Table 4 ,the IMP will be administered open-label at a starting dose of 4 mg/kg BID for 
2 weeks. Following DSMC review and approval of each  dose titration, participants will be up-titrated to 
8 mg/kg BID for 2 weeks, and then to the 12 mg/kg BID dose . The participant will then continue on the 
assigned dose (or highest dose tolerated) for the remainder of the 13 weeks. The process for DSMC 
review of dose escalation is described in Section 7.2.2 . 
Table 4 Dose Titration Schedule
Week 1 and
Week 2Week 3 Week 4 
and
Week 5Week 6 Week 7 
and 
Week 8Week 9 Week 10 to 
Week 13
4 mg/kg 
BID 
(8 mg/kg 
daily)4 mg/kg BID (8 mg/kg daily)
18 mg/kg BID 
(16 mg/kg 
daily)8 mg/kg BID (16 mg/kg 
dail
y)112 mg/kg 
BID 
(24 mg/kg 
daily)12 mg/kg BID (24 mg/kg 
dail
y)12 mg/kg 
BID 
(24 mg/kg 
daily) DSMC 
Reviews Data 
Prior to Up-
Titration2 DSMC 
Reviews Data 
Prior to Up-
Titration2 DSMC 
Reviews Data 
After 2 weeks 
on 12 mg/kg 
to Confirm 
Safet y2
BID = twice daily; DSMC = Da ta Safety Moni toring Committee
1Participants will stay on their current dose until the data is reviewed by the Da ta Safety Monitoring Committee (DSMC)
2Expected time for DSMC review will be one week.
The dose titration schedule may be modified based  on updated PK modelling incl uding data from the 
study.
7.2.1 Adjustment of the Dose for Tolerability
The dose for each participant is based on the participant’s weight at Baseline (Visit 3). The dose will not 
be increased or decreased if the participant’s weight  at a postbaseline visit changes. Within the up-
titration period, if a participant is deemed not to be tolerating the current dose within the 2-week period 
for that dose, and they have not met any of the stopping criteria (Section 9.4.5 ), they can be down-titrated 
to the next lowest dose in the titration schedule. The  Investigator must attempt to increase the dose as 
soon as it is possible based on the clinical situation. The aim is to return to the or iginally assigned dose. If 

Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 48 of 112 the originally assigned dose cannot be reached or the pa rticipant is again unable to  tolerate that dose, the 
Investigator will continue treatment on the highest dose  that the participant can tolerate. The process for 
DSMC review of dose escala tion is described in section 7.2.2.  
 
7.2.2 Dose Escalation Review by the DSMC 
Data from two weeks of dosing at each dose in the do se escalation will be reviewed by the DSMC before 
participants are allowed to be administered the next highest dose. Participants will stay on their current 
dose until the DSMC has reviewed the data and approved  the participants to escalate to the next dose.  
 
After eligibility is confirmed, the participant will be administered NNZ-2591 IMP open label at a starting 
dose of 4 mg/kg BID for a total of approximately 3 we eks. After 2 weeks of dosing at 4 mg/kg BID, the 
DSMC will review the safety data. The participan t will remain on the starting dose during the DSMC 
review. If the DSMC determines that tolerability  and safety during the 2-week dosing period are 
acceptable, the participant will escalate to the ne xt dose of 8 mg/kg BID and be dosed for a total of 
approximately 3 additional weeks at that dose. After 2 weeks of dosing at 8 mg/kg BID, the DSMC will 
review the safety data. If the DSMC determines th at tolerability and safety during the 2-week dosing 
period on 8 mg/kg BID are acceptable, the participant w ill then escalate to the target dose of 12 mg/kg 
BID and be dosed for 2 weeks. After 2 weeks of do sing at 12 mg/kg BID, the DSMC will review the 
safety data to determine if the participant can con tinue dosing at 12 mg/kg BID for the remainder of the 
13 weeks.   The DSMC will determine if dose escalation ca n proceed based on pre-specified stopping rules 
summarized for individual participants in Section 9.4.5.  Note that early cessation of IMP treatment does 
not necessarily mean the participant is withdraw n from the study. With any early cessation, all 
evaluations and tests scheduled during the study must be conducted if possible. 
 
The site will inform the caregiver of the up-titrati on decisions as soon as possible after the site has 
received the official notification of the DSMC decision. The site will verify with the caregiver that instructions to up-titrate to 8 mg/kg BID have been fo llowed at the Week 4 visit (Visit 7), and will verify 
with the caregiver that instructions to up-titrate to 12 mg/kg BID have been followed at the Week 7 visit 
(Visit 10). If the DSMC has not yet approved the particip ant to escalate to the next dose by the time of the 
relevant visit, the site should contact the caregiver within 24 hours of receiving the decision from the DSMC. If the participant is not approved to titrate to the next dose, the site will contact the caregiver to 
discuss appropriate follow-up as is cl inically indicated. At each visit, the clinician or nurse should check 
the dose when reviewing the caregiver diary.   
7.3 Treatment Assignment 
This is an open-label study in which all participan ts will be assigned to NNZ-2591 Oral Solution, 
50mg/mL and receive 13 weeks of treatment. All partic ipants will be titrated to the dose of 12 mg/kg BID 
or the highest tolerated dose based  on the Dosing Schedule in Section 7.2. The dose titration schedule 
may be modified based on updated PK modelling including  data from the study. 
Participants who are unable to tolerate the study treatment may be discontinued from the study.  
If a participant meets all eligibility criteria and written informed consent has been  provided by a legally 
authorized representative, the participan t will be enrolled in the study.   
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 49 of 112 7.4 Study Timeline 
The study duration is 19 weeks from Screening to Follow-Up at Week 15 (+4 days).  
7.5 COVID-19 
As a result of the Coronavirus disease (COVID-19) p ublic health emergency, this protocol includes 
provision for alternative methods of  performing safety and efficacy a ssessments in accordance with the 
FDA Guidance on Conduct of Clinical Trials of Me dical Products during the COVID-19 Public Health 
Emergency .** Provision is made for off-site  assessments where necessary an d all efforts have been made 
to ensure the alternative processes are consistent as mu ch as possible with in-clinic visits. For visits that 
are designated as in-clinic, an actual in-clinic vis it is preferred. However, an off-site visit may be 
conducted for a scheduled in-clinic visit in extenuatin g circumstances due to the COVID-19 health crisis 
with the prior approval of the Sponsor and Medical Monitor. Clinical investigators are to document the 
reason for any contingency measures implemented. If at any time in the study, the participant or his or her caregiver tests SRVLWLYH IRUVHYHUH DFXWH UHVSLUD WRU\ V\QGURPH FRURQDYLUXV 6$56 -CoV-2) or becomes 
ill with symptoms of COVID-19, the family should be instructed to contact the site as soon as possible. Once informed, the Investigator should contact the Medical Monitor. 
8. PARTICIPANT POPULATION  
Approximately 10 to 20 male and female participants between the ages of 3 and 17 years, inclusive, are 
planned to complete the study, balanced to the extent possible by age and the number of males and 
females. 
The participants will be categorized by age in three groups: 13 to 17-year-olds (Group 1), 8 to 12-year-
olds (Group 2), and 3 to 7-year-olds (Group 3). Enrollment will be bala nced to the extent possible by sex 
and age with a minimum of 3 males and 3 females acro ss all age groups, and a minimum of 3 participants 
in each age group.  Enrollment will proceed by age group according to the following process. Enrollment will commence first 
in the oldest age group (Group 1). After at least three participants in Group 1 have received two weeks of 
treatment at the starting dose, safety, and tolerability data will be reviewed by the DSMC.  If tolerability 
and safety for those participants during that peri od is deemed acceptable, enrollment for Group 2 will 
proceed and dosing will commence at the starting dose. When at least th ree participants in Group 2 have 
received two weeks of treatment at the starting dose, sa fety and tolerability data will be reviewed by the 
DSMC. If tolerability and safety for Group 2 is deemed acceptable, enrollment for Group 3 will 
commence and dosing will begin at the starting dos e. Participants in the younger age groups may be 
screened and enter the 4 to 6 week Screening period before DSMC review, but they will not be enrolled 
or dosed until the DSMC has reviewed and approved  the initiation of dosing in the younger age group.  
 
** FDA Guidance on Conduct of Clinical Trials of Me dical Products During the COVID-19 Public Health 
Emergency: Guidance for Industry, Investigators, a nd Institutional Review Boards (Center for Biologics 
Evaluation and Research; Center for Devices and Ra diological Health; Center for Drug Evaluation and 
Research; Office of the Commissioner; Office of Clinical Policy and Programs; Office of Clinical Policy; 
Office of Good Clinical Practice) (2021). 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 50 of 112 8.1 Inclusion Criteria 
To be eligible for this study, par ticipants must meet all of the inclusion criteria and none of the exclusion 
criteria. Inclusion criteria include: 
1. Clinical diagnosis of PTHS with a documented disease-causing genetic etiology for the disorder.  
2. Males or females aged 3 to 17 years at Screening, inclusive. 
3. Body weight of 12 kg or higher at Screening. We ight measurements may be repeated during the 
Screening period in consultation with the Medical Monitor. 
4. Participants with a Clinical Global Impression – Severity (CGI-S) score of 4 or greater at the 
Screening visit. 
5. Not currently actively undergoing regression or loss  of skills defined as no persistent loss of 
previously acquired developmental skills for a pe riod within 3 months of the Screening visit. 
a. Previously acquired skills include any skill esta blished and used on a daily basis for at 
least 3 months. 
b. Variations in use of skills that is part of a general pattern of ups and downs, as 
determined by the investigator, are not counted as regression. 
c. Skills may include language, non-verbal comm unication, fine motor skills, ambulation 
(including gait, coordination, independence of walking/standing), social skills, play, self-
help.  
6. Each participant must be able to swallow the IMP provided as a liquid solution.  
7. The participant’s caregiver(s) must have sufficient  English language skills  to complete caregiver 
assessments in English. 
 
8.2 Exclusion Criteria 
To be eligible for this study, par ticipants must meet all of the inclusion criteria and none of the exclusion 
criteria. Exclusion criteria include: 
     Laboratory and Screening Values 
1. Body weight < 12 kg at Screening. Weight may be repeated during the Screening period in 
consultation with the Medical Monitor. 
2. HbA1c values above 7% at Screening. 
3. Clinically significant abnormalities in safety labo ratory tests (as determined by the Investigator) 
in safety laboratory values, vital signs, as meas ured at the Screening visit. Laboratory testing 
may be repeated during the Screening period in consultation with the Medical Monitor. 
4. Positive pregnancy test at the Screening visit. 
5. QTcF Exclusions (any of the following): 
a. Screening QTcF interval of > 450 ms assessed using Fridericia’s correction factor based on 
12-lead ECG obtained as a continuo us ECG of at least 50 seconds. 
b. Hypokalemia (Serum potassium at the Screen ing visit < 3.0 mmol/L or mEq/L). Serum 
potassium may be repeated during the Screeni ng period with the agreement of the Medical 
Monitor. 
c. QTcF prolongation that is currently controlle d with medication, in which normal QTcF 
intervals can only be achieved with medication. 
6. Any other clinically significant finding (as determined by the Investigator) on ECG at the 
Screening visit that would increase the likelihood of a severe arrhythmia. 
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 53 of 112 antibiotics, pain relievers, anti-diarrheals, and laxatives) whose doses and dosing regimen have 
not been stable for at least 4 weeks prior to the Screening visit. If the treatment was 
discontinued, the discontinuation must have oc curred no fewer than 2 weeks prior to the 
Screening visit. 
a. This includes nutraceutical treatments a nd cannabinoids (tetrahydrocannabinol [THC] 
and cannabidiol [CBD]) which are allowable but also must meet the stability conditions 
above. 
b. Pain relievers and laxatives may be used as needed.  
c. Standard of care immunizations and vaccinations (including COVID-19) are allowed and 
are not subject to the ab ove stability conditions. 
d. The Investigator should consult with the medica l monitor if a participant is being treated 
with ocular toxic, hepatotoxic, ne phrotoxic or antibiotic medications.  
e. If the Investigator is unsure if a medica tion is permitted, the Medical Monitor should 
confirm if the medication is allowed and will provide written documentation to support 
the use of the medication, if allowed. 
 Regression of Skills  
37. Actively undergoing regression or loss of skills defined as a persistent loss of previously 
acquired developmental skills within 3 months of the Screening visit.  
a. Previously acquired skills include any skill esta blished and used on a daily basis for at 
least 3 months. 
b. Variations in use of skills that is part of a general pattern of ups and downs, as 
determined by the investigator, are not counted as regression. 
c. Skills may include language, non-verbal comm unication, fine motor skills, ambulation 
(including gait, coordination, independence of walking/standing), social skills, play, self-
help.  
 Seizures 
 
38. Seizure profile that is not stable 8 weeks prio r to commencing IMP. The overall pattern of 
seizure activity for the participant should be consis tent with their typical pattern of seizures and 
be stable within the 8-week period in terms of  type, intensity, duration, and frequency as 
determined by the clinical Investigator.  
 
Medical Conditions  
39. Currently pregnant, lactating, or breastfeeding. 
40. Current clinically significant (as determined by the Investigator) cardiovascular, gastrointestinal, respiratory, or endocrine diseas e, or clinically significant organ impairment. 
The Investigator may consult with the Medical M onitor as needed if he/she is uncertain if 
symptoms are exclusionary. 
41. Current clinically significant (as determined by the Investigator) hypo- or hyperthyroidism. If 
the participant has hypo- or hyperthyroidism that is controlled with medication, the Investigator 
should consult with the Medical Monitor to confirm if the participant is eligible. 
42. Type 1 or Type 2 diabetes mellitus requiring in sulin (whether well controlled or uncontrolled), 
or uncontrolled Type 1 or Type 2 diabetes.  
43. Has planned surgery during the study. 
44. History of, or  current, cerebrovascular disease or brain trauma. 
45. History of, or current catatonia or catatonia-like symptoms. 
46. History of, or current, malignancy.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 56 of 112 the physical and neurological exam will  be completed by the Investigator at the telemedicine visits based 
on the guidance documents provided to the Investigat or. During the in-home component of the visit at 
Screening (Visit 2), the nurse will collect vital signs,  weight, do a Targeted Physical Exam assessing 
general appearance, abdominal/costovertebral angel tenderness (CVA), and edema, and query oral intake. 
The nurse will review the caregiver diary during the vi sit and provide the caregiver with a new section of 
the diary. Post-enrollment, at the in-home component of the combined visit, the nurse will collect urine, 
vital signs, weight, and blood samples for a comprehe nsive metabolic panel (CMP), complete blood count 
(CBC) with differential, and coagulation (except Visit 1, when only CMP is collected).  The nurse will 
conduct a Targeted Physical Exam assessing: gene ral appearance; the abdomen and the CVA region for 
tenderness; the extremities and peri-orbital region fo r edema. A suprapubic exam (bladder palpation) to 
assess for urinary retention may be performed. The visiting nurse will also review the caregiver diary, 
provide the caregiver with a new diary section, query oral intake, and a review tolerability. At the post-
treatment follow-up visit at Week 15, the visiting nurse  will also collect a 12-lead ECG, in addition to the 
above assessments. 
 In-home only visits with a visiting nurse will be done at Weeks 3 (Visit 6), 5 (Visit 8), 7 (Visit 10), 9 
(Visit 12), 11 (Visit 14), and 12 (Visit 15). At these visits, the nurse will collect urine, vital signs, weight, 
and a blood sample for the CMP. The nurse will also conduct a Targeted Physical  Exam assessing general 
appearance, abdominal/CVA, and edema. A suprapubic exam (bladder palpation) to assess for urinary retention may be performed. The vi siting nurse will review the caregive r diary, query oral intake, and 
review tolerability.   A combined remote visit or nurse-only in-home visit may be conducted in-clinic by the study staff if 
agreed upon by the Investigator and the caregiver. The site should inform the nursing service of such a 
change. If an unscheduled nurse visit is needed for follo w-up (e.g. repeat labs or other assessments), this 
can be requested by the site with the nursing service. The site should inform the Medical Monitor if they 
require an unscheduled nursing visit or w ill conduct a remote visit in the clinic. 
 The nurse will send a report for all in-home nurse visits to the Investigator along with a copy of the 
completed Caregiver Diary. The Investigator is responsible for reviewing the Caregiver Diary and 
determining if any issues should be reported as an a dverse event or require follow up. The visiting nurse 
will escalate any issues related to potential AE/SAEs, st opping criteria, major dosing issues or issues of 
potential safety concern to the Investigator the same day. Any chan ges noted will be provided to the 
Investigator who will be responsible fo r determining and reporting AE/SAEs.  
9.2 Study Procedures by Visit 
9.2.1 Visit 1 Screening/Baseline (in-clinic) – Week -4 ( rr 2 days) 
The following assessments will be conducte d and data collected during Visit 1: 
x Eligibility 
o Informed consent (mandatory) 
o Consent for reuse of leftover Biomarker and PK samples (optional) 
o Inclusion/exclusion criteria 
o Medical history  
o Confirm documented PTHS diagnosis and genotype 
o PTHS history and exam 
o Confirm co-morbid psychiatric disorders by Diag nostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5)  
o Autism Mental Status Exam 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 58 of 112 Remote/Telemedicine – Investigator and Appropriate Staff 
The following assessments will be cond ucted and data collected during Visit 2, conducted by the site via 
telemedicine or video facilities as appropriate. Care giver assessments must be completed the day of the 
visit or no earlier than the day before the visit (exc ept the caregiver diary which is completed daily) and 
reviewed by the Investigator. 
x Medical history (any updates since Visit 1) 
x Review of the Caregiver Diary (con-meds, seizures , voids, oral intake, breathing events, changes in 
symptoms)  
 
Caregiver Assessments 
The following assessments should be completed by  the caregiver. Caregiver assessments must be 
completed the day of the visit or no earlier than the day before the visit. 
x Efficacy 
o Caregiver Top 3 Concerns  
o ABC-2 
o CSHQ 
o GIHQ 
 
In-home Nurse Visit 
The following assessments should be conducted, an d data collected by the visiting nurse in the 
participant’s home during Visit 2: 
 
x Vital Signs 
x Targeted Physical Exam: abdominal, CVA tenderne ss, general appearance, edema. Exam may include 
suprapubic exam (bladder palpation) to assess for ur inary retention if decreased urine output is noted. 
x Weight 
x Review of Caregiver Diary 
 
9.2.3 Visit 3 Baseline (in-clinic) – Week 0 ( rr 2 days) 
The following assessments will be conducted and data collected during the Baseline visit (Visit 3). 
Caregiver assessments must be completed the day of th e visit or no earlier than the day before the visit 
(except the caregiver diary which is comple ted daily) and reviewed by the Investigator. 
 
x Eligibility 
o Review inclusion/exclusion criteria 
o Medical history (updates from Screening visit) 
o Rapid SARS-CoV-2 test 
x Safety 
o Physical and neurological examination 
o Vital signs 
o Height/length 
o Weight 
o 12-lead ECG 
o CBC with differential 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 59 of 112 o Coagulation 
o CMP 
o Urinalysis 
x Review of the Caregiver Diary (con-meds, seizur es, voids, oral intake, breathing events, changes 
in symptoms) 
x Biomarkers 
o Blood sample for biomarkers 
o Stool sample for microbiome 
x Efficacy 
o CGI-S 
o Vineland Adaptive Behavior Scales-3 
o MB-CDI 
o ORCA 
o Caregiver Top 3 Concerns  
o ABC-2 
o BPI-SF 
o ICND 
o QI-Disability 
o CSHQ 
o GIHQ 
o Modified two-minute walk test 
The Baseline visit (Visit 3) may be conducted over three consecutive days. It is preferrable that ECGs, 
safety labs and biomarker sample collection are condu cted on the same day. All assessments must be 
completed within the two-day window for the visit (visit  day ± 2 days).  For Visit 3, all assessments must 
be completed before administration of the IMP.  
x In-clinic administration of first dose 
o The first dose of IMP will be administered in  the clinic after all Baseline assessments are 
completed, or, if the Investigator judges that it is too late in the day, on the following day. 
The participant should be monitored for at least three hours post the first dose.  
o If the first dose is administered the day following Baseline, vital signs (except height) 
should be collected before th e first dose is administered. 
o The dose can be taken orally from a cup or from a dosing syringe. 
o Doses should be given on an empty stomach (2  hours after the previous meal or snack 
and 30 minutes prior to the next). 
o The IMP should not be mixed with water, liquid thickeners, or food for administration.   
o Day 1 of dosing is defined by the date when the first dose is taken. At this visit, t he site 
will dispense an adequate supply of IMP for dispensing by th e caregiver at home.  
9.2.4 Visit 4 Treatment Period (telemedi cine and in-home) – Week 1 ( rr 1 day) 
Visit 4 (Week 1) will be a remote telemedicine and in-home visit. The assessme nts to be conducted and 
data collected are divided accordingly below.  
Remote/Telemedicine – Investigat or and Appropriate Site Staff 
The following assessments and data w ill be conducted or collected by the site via telemedicine or video 
facilities as appropriate during Vis it 4. Caregiver-completed assessme nts should be reviewed by the 
Investigator.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 60 of 112 x Recent Clinical History 
x AE/SAE and tolerability review 
x Review of the Caregiver Diary (dosing, con-meds, se izures, voids, oral intake , changes in symptoms)  
 
Caregiver Assessments 
The following assessments should be  completed by the caregiver.  
x Caregiver diary 
 
In-home Nurse Visit 
 The in-home visit will be conducted by a visiting nur se. The nurse will escalate any issues related to 
AE/SAEs, stopping criteria, major dosing issues or i ssues of potential safety co ncern to the Investigator 
via telephone the same day. Any changes noted will  be provided to the Investigator who will be 
responsible for determini ng and reporting AE/SAEs.  
 The following assessments should be conducted, an d data collected by the visiting nurse in the 
participant’s home during Visit 4: 
x AE/SAE/tolerability query 
x Review caregiver diary: concomitant medications, voids, oral intake, a nd changes in symptoms 
x Review Dosing Compliance 
x Collect blood for CMP 
x Collect urine for urinalysis 
x Vital Signs 
x Weight 
x Targeted Physical Exam: general ap pearance, abdominal, CVA tenderness , check for edema. Exam 
may include a suprapubic exam (bla dder palpation) to assess for urinary retention may be performed 
if decreased urine output is noted. 
 
9.2.5 Visit 5 Treatment Period (in-clinic) – Week 2 ( rr 2 days) 
Visit 5 (Week 2) will be an in-clinic visit. This vi sit may be conducted over three consecutive days. The 
following assessments should be conducted and data  collected by site personnel during this visit. 
Caregiver assessments must be completed the day of th e visit or no earlier than the day before the visit 
(except the Caregiver Diary which is completed daily ) and reviewed by the Investigator. All assessments 
must be completed within the window for the visit (visit day ±2 days). 
x Safety 
o Recent clinical history 
o Physical and neurological examination 
o Vital signs 
o Weight 
o Review for AEs/SAEs 
o 12-lead ECG 
o CBC with differential 
o Coagulation 
o CMP  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 61 of 112 o Urinalysis 
x Caregiver Diary (con-meds, seizures, voids, oral intake, breathing events , changes in symptoms) 
x Review Dosing Compliance 
x Pharmacokinetics/Pharmacodynamics 
o Blood sampling for PK 
 
9.2.6 Visit 6 Treatment Period (i n-home nurse) – Week 3 ( rr1 day) 
The in-home visit at Visit 6 (Week 3) will be conduc ted by a visiting nurse. The nurse will escalate any 
issues related to AE/SAEs, stopping criteria, major dos ing issues or issues of potential safety concern to 
the Investigator via telephone the same day. Any chan ges noted will be provided to the Investigator who 
will be responsible for determ ining and reporting AE/SAEs.  
The following assessments should be conducted, an d data collected by the visiting nurse in the 
participant’s home during Visit 6: 
x AE/SAE/tolerability query 
x Review caregiver diary: concomitant medications , voids, oral intake, changes in symptoms 
x Review Dosing Compliance 
x Collect blood for CMP 
x Collect urine for urinalysis 
x Vital Signs 
x Weight 
x Targeted Physical Exam: general appearance, abdo minal, CVA tenderness, check for edema. Exam 
may include a suprapubic exam (bla dder palpation) to assess for urinary retention if decreased urine 
output is noted if decreased urine output is noted. 
 
9.2.7 Visit 7 Treatment Period (telemedi cine and in-home) – Week 4 ( r1 day) 
Visit 7 (Week 4) will be a remote telemedicine and in-home visit. The assessme nts to be conducted and 
data collected are divided accordingly below.  
Remote/Telemedicine – Investigat or and Appropriate Site Staff 
The following assessments and data w ill be conducted or collected by the site via telemedicine or video 
facilities as appropriate during Vis it 7. Caregiver-completed assessme nts should be reviewed by the 
Investigator.  
x Recent Clinical History 
x Modified neurological exam 
x Modified physical exam 
x AE/SAE and tolerability review 
x Inform visiting nurse of dose titration, and confirm th at dose titration instructions have been followed 
by the caregiver. 
x Review of the Caregiver Diary (con-meds, seizur es, voids, oral intake, changes in symptoms)  
 
Caregiver Assessments 
The following assessments should be  completed by the caregiver.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 62 of 112 x Caregiver diary 
 
In-home Nurse Visit 
 
The in-home visit will be conducted by a visiting nur se. The nurse will escalate any issues related to 
AE/SAEs, stopping criteria, major dosing issues or i ssues of potential safety co ncern to the Investigator 
via telephone the same day. Any changes noted will  be provided to the Investigator who will be 
responsible for determini ng and reporting AE/SAEs.  
 The following assessments should be conducted, an d data collected by the visiting nurse in the 
participant’s home during Visit 7:  
x AE/SAE/tolerability query 
x Review caregiver diary: concomitant medications, voids, oral intake, and changes in symptoms 
x Review Dosing Compliance 
x Collect blood labs 
o CBC with differential 
o Coagulation 
o CMP 
x Collect urine for urinalysis 
x Vital Signs 
x Weight 
x Targeted Physical Exam: general appearance, abdo minal, CVA tenderness, check for edema. Exam 
may include a suprapubic exam (bla dder palpation) to assess for urinary retention if decreased urine 
output is noted. 
 
9.2.8 Visit 8 Treatment Period (i n-home nurse) – Week 5 ( rr1 day) 
The in-home visit at Week 5 (Week 8) will be conduc ted by a visiting nurse. The nurse will escalate any 
issues related to AE/SAEs, stopping criteria, major dos ing issues or issues of potential safety concern to 
the Investigator via telephone the same day. Any chan ges noted will be provided to the Investigator who 
will be responsible for determ ining and reporting AE/SAEs.  
The following assessments should be conducted, an d data collected by the visiting nurse at the 
participant’s home during Visit 8: 
x AE/SAE/tolerability query 
x Review caregiver diary: concomitant medications , voids, oral intake, changes in symptoms 
x Review Dosing Compliance 
x Collect blood for CMP 
x Collect urine for urinalysis 
x Vital Signs 
x Weight 
x Targeted Physical Exam: general appearance, abdo minal, CVA tenderness, check for edema. Exam 
may include suprapubic exam (bladder palpation) to assess for urinary retention if decreased urine 
output is noted. 
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 63 of 112 9.2.9 Visit 9 Treatment Period (in-clinic) – Week 6 ( rr 2 days) 
Visit 9 (Week 6) is an in-clinic visit. The followi ng assessments will be conducted and data collected 
during Visit 9. This visit may be conducted over thr ee consecutive days. Caregiver assessments must be 
completed the day of the visit or no earlier than the day before the visit (except the caregiver diary which 
is completed daily) and reviewed by the Investigat or. All assessments must be completed within the 
window for the visit (visit day ±2 days). 
 
x Safety 
o Recent clinical history 
o Physical and neurological examination 
o Vital signs 
o Weight 
o Review for AEs/SAEs 
o 12-lead ECG 
o CBC with differential 
o Coagulation 
o CMP 
o Urinalysis 
o TSH, Free T3, Free T4 
o Serum Pregnancy Test (for female par ticipants who have reached menarche) 
x Caregiver Diary (dosing, con-meds, seizures, voids, oral intake, breathing events, changes in 
symptoms) 
x Review Dosing Compliance 
x Pharmacokinetics/Pharmacodynamics 
o Blood sampling for PK 
x Efficacy 
o CGI-I 
o CGI-S 
o Caregiver Top 3 Concerns  
o ABC-2 
o CSHQ 
o GIHQ 
9.2.10  Visit 10 Treatment Period (in-home nurse) – Week 7 ( r1 day) 
The in-home visit at Week 7 (Visit 10) will be condu cted by a visiting nurse. The nurse will escalate any 
issues related to AE/SAEs, stopping criteria, major dos ing issues or issues of potential safety concern to 
the Investigator via telephone the same day. Any chan ges noted will be provided to the Investigator who 
will be responsible for determ ining and reporting AE/SAEs.  
At Week 7, the site will also have a phone call with the caregiver to confirm the instructions for the dose 
titration have been followed. The site will also inform  the visiting nurse so the dosing schedule can be 
reviewed with the family during the in-home visit.  
The following assessments should be conducted, an d data collected by the visiting nurse in the 
participant’s home during Visit 10: 
x AE/SAE/tolerability query 
x Review caregiver diary: concomitant medications , voids, oral intake, changes in symptoms 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 64 of 112 x Review Dosing Compliance 
x Collect blood for CMP 
x Collect urine for urinalysis 
x Vital Signs 
x Weight 
x Targeted Physical Exam: general appearance, abdo minal, CVA tenderness, check for edema. Exam 
may include a suprapubic exam (bla dder palpation) to assess for urinary retention if decreased urine 
output is noted. 
 
9.2.11  Visit 11 Treatment Period (telemedicine and in-home) – Week 8 ( rr 1 day) 
Visit 11 (Week 8) will be a remote telemedicine and in-home visit. The assessments to be conducted and 
data collected are divided accordingly below.  
Remote/Telemedicine – Investigator and Appropriate Site Staff 
The following assessments and data w ill be conducted or collected by the site via telemedicine or video 
facilities as appropriate during Visit 11. Caregiver- completed assessments should be reviewed by the 
Investigator.  
x Recent Clinical History 
x Modified neurological exam 
x Modified physical exam 
x AE/SAE and tolerability review 
x Review of the Caregiver Diary (dosing, con-meds, se izures, voids, oral intake , changes in symptoms)  
 
Caregiver Assessments 
The following assessments should be  completed by the caregiver.  
x Caregiver diary 
 
In-home Nurse Visit 
 
The in-home visit will be conducted by a visiting nur se. The nurse will escalate any issues related to 
AE/SAEs, stopping criteria, major dosing issues or i ssues of potential safety co ncern to the Investigator 
via telephone the same day. Any changes noted will  be provided to the Investigator who will be 
responsible for determini ng and reporting AE/SAEs.  
 The following assessments should be conducted, an d data collected by the visiting nurse in the 
participant’s home during Visit 11: 
x AE/SAE/tolerability query 
x Review caregiver diary: concomitant medications , voids, oral intake and changes in symptoms 
x Review Dosing Compliance 
x Collect blood labs 
o CBC with differential  
o Coagulation 
o CMP 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 65 of 112 x Collect urine for urinalysis 
x Vital Signs 
x Weight 
x Targeted Physical Exam: general appearance, abdo minal, CVA tenderness, check for edema. Exam 
may include a suprapubic exam (bla dder palpation) to assess for urinary retention if decreased urine 
output is noted. 
 
 
9.2.12  Visit 12 Treatment Period (in-home nurse) – Week 9 ( rr 1 day) 
The in-home visit at Week 9 (Visit 12) will be condu cted by a visiting nurse. The nurse will escalate any 
issues related to AE/SAEs, stopping criteria, major dos ing issues or issues of potential safety concern to 
the Investigator via telephone the same day. Any chan ges noted will be provided to the Investigator who 
will be responsible for determ ining and reporting AE/SAEs.  
 The following assessments should be conducted, an d data collected by the visiting nurse in the 
participant’s home during Visit 12: 
x AE/SAE/tolerability query 
x Review caregiver diary: concomitant medications, voids, oral intake, changes in symptoms 
x Review Dosing Compliance 
x Collect blood for CMP 
x Collect urine for urinalysis 
x Vital Signs 
x Weight 
x Targeted Physical Exam: general ap pearance, abdominal, CVA tenderness , check for edema. Exam 
may include a suprapubic exam (bla dder palpation) to assess for urinary retention if decreased urine 
output is noted. 
 
9.2.13  Visit 13 Treatment Period (telemedicine and in-home) – Week 10 ( r1 day) 
Visit 13 (Week 10) will be a remote telemedicine and in-home visit. The assessments to be conducted and 
data collected are divided accordingly below.  
Remote/Telemedicine – Investigator and Appropriate Site Staff 
The following assessments and data w ill be conducted or collected by the site via telemedicine or video 
facilities as appropriate during Visit 13. Caregiver- completed assessments should be reviewed by the 
Investigator.  
x Recent Clinical History 
x Modified neurological exam 
x Modified physical exam 
x AE/SAE and tolerability review 
x Review of the Caregiver Diary (dosing, con-meds, se izures, voids, oral intake , changes in symptoms)  
 
Caregiver Assessments 
The following assessments should be  completed by the caregiver.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 66 of 112 x Caregiver diary 
 
In-home Nurse Visit 
 
The in-home visit will be conducted by a visiting nur se. The nurse will escalate any issues related to 
AE/SAEs, stopping criteria, major dosing issues or i ssues of potential safety co ncern to the Investigator 
via telephone the same day. Any changes noted will  be provided to the Investigator who will be 
responsible for determini ng and reporting AE/SAEs.  
 The following assessments should be conducted, an d data collected by the visiting nurse at the 
participant’s home during Visit 13: 
x AE/SAE/tolerability query 
x Review caregiver diary: concomitant medications , voids, oral intake, and changes in symptoms 
x Review Dosing Compliance 
x Collect blood labs 
o CBC with differential  
o Coagulation 
o CMP 
x Collect urine for urinalysis 
x Vital Signs 
x Weight 
x Targeted Physical Exam: general appearance, abdo minal, CVA tenderness, check for edema. Exam 
may include a suprapubic exam (bla dder palpation) to assess for urin ary retention if decreased urine 
output is noted. 
 
9.2.14  Visit 14 Treatment Period – (in-home nurse) Week 11 ( rr1 day) 
The in-home visit at Week 11 (Visit 14) will be condu cted by a visiting nurse. The nurse will escalate any 
issues related to AE/SAEs, stopping criteria, major dos ing issues or issues of potential safety concern to 
the Investigator via telephone the same day. Any chan ges noted will be provided to the Investigator who 
will be responsible for determ ining and reporting AE/SAEs.  
 
The following assessments should be conducted, an d data collected by the visiting nurse in the 
participant’s home during Visit 14: 
x AE/SAE/tolerability query 
x Review caregiver diary: concomitant medications , voids, oral intake, changes in symptoms 
x Review Dosing Compliance 
x Collect blood for CMP 
x Collect urine for urinalysis 
x Vital Signs 
x Weight 
x Targeted Physical Exam: general appearance, abdo minal, CVA tenderness, check for edema. Exam 
may include a suprapubic exam (bla dder palpation) to assess for urinary retention if decreased urine 
output is noted. 
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 68 of 112 o HbA1c 
x Review Caregiver Diary (con-meds, seizures , breathing events, changes in symptoms) 
x Review Dosing Compliance 
x Pharmacokinetics/Pharmacodynamics 
o Blood sampling for PK 
x Biomarkers 
o Blood sample for biomarkers 
o Stool sample for microbiome 
x Efficacy 
o CGI-I 
o CGI-S 
o SB5 or Bayley-4 (Bayley is completed for participants who cannot  achieve a basal on 
SB5) 
o Vineland Adaptive Behavior Scales-3 
o ASME 
o MB-CDI 
o ORCA 
o Caregiver Top 3 Concerns  
o ABC-2 
o BPI-SF 
o Caregiver Impression of Change 
o ICND 
o QI-Disability 
o CSHQ 
o GIHQ  
o Modified two-minute walk test  
9.2.17  Visit 17 Follow-up (telemedicine and in-home) – Week 15 (+ 4 days) 
Visit 17 (Week 15, Follow-up) will be a remote and in -home visit. The assessme nts to be conducted and 
data collected are divided accordingly below.  
Remote/Telemedicine – Investigat or and Appropriate Site Staff 
The remote visit will be conducted by the site vi a telemedicine or video facilities as appropriate. 
Caregiver assessments must be completed the day of th e visit or no earlier than the day before the visit 
(except the caregiver diary which is comple ted daily) and reviewed by the Investigator. 
The Investigator will also query changes in tolera bility and note any changes. The Investigator is 
responsible for determini ng and reporting any changes that qualify as AEs. 
The following assessments will be co nducted and data collected or revi ewed by site personnel during 
Follow-up: 
x Safety 
o Recent clinical history 
o Physical and neurological examination: A modified version of the physical and 
neurological exam will be done based on  the guidance document provided to the 
Investigator. 
o Review for AEs/SAEs 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 69 of 112 x Review Caregiver Diary (dosing, con-meds, se izures, voids, oral in take, breathing events, 
changes in symptoms) 
x Efficacy 
o CGI-I 
o CGI-S 
o Caregiver Top 3 Concerns  
o ABC-2 
o CSHQ 
o GIHQ 
x Study Exit Form 
 
In-home Nurse Visit 
 
The in-home visit will be conducted by a visiting nurse who will also query any changes in tolerability during the in-home visit. Any changes will be noted and provided to the Investigator.  
 
The following assessments will be conducted and data collected by the home nurse during Follow-up: 
 
x AE/SAE/tolerability query 
x Review caregiver diary: dosing, concomitant medications, voids, oral  intake, changes in symptoms 
x Collect blood:  
o CMP 
o CBC with differential 
o Coagulation 
x Collect urine for urinalysis 
x Vital Signs 
x Weight 
x 12-lead ECG 
x Targeted Physical Exam: general appearance, abdominal, CVA tenderness, check for edema. Exam 
may include a suprapubic exam (bla dder palpation) to assess for urinary retention if decreased urine 
output is noted. 
 
9.3 Screening and Baseline Procedures 
Screening and Baseline assessments are complete d after informed consent during a period of 
approximately 4 to 6 weeks. During the Screening/Baselin e period data will also be collected to establish 
the participant’s baseline characteri stics and symptom severity based on assessments collected during the 
4 to 6 week period. There are two in-clinic visits and one remote/in-home visit for Screening and Baseline 
(Visits 1, 2, 3). Screening (Visit 1, in-clinic), Scr eening Visit 2, (combined remote/in-home nurse visit), 
Baseline (Visit 3, in-clinic). The second visit during the Screening period (Visit  2) should be conducted 2 
weeks ± 1 day after the Screening visit (Visit 1) . The participant will then remain in Screening for an 
additional 2 to 4 weeks. The caregiver diary must be  completed daily during the entire Screening period 
whether it is 4 weeks or 6 weeks. 
 
During the Screening visit (Visit 1) informed consent to  participate in the study will be obtained from the 
parent or legally authorized representative.   
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 71 of 112 9.4 Treatment of Participants 
9.4.1 Investigational Medicinal Product 
Full information regarding the preparation, storage,  and administration of NNZ-2591 Oral Solution, 50 
mg/mL is provided in the Pharmacy Manual. NNZ-2591 IMP is provided as a ready-to-use strawberry-
flavored liquid for oral administration. 
 
9.4.2 Investigational Medicinal Product Administration 
NNZ-2591 Oral Solution, 50 mg/mL will be administered  open-label at a target dose of 12 mg/kg BID. 
The total administration period for NNZ-2591 will be 13 weeks. Participants will be up-titrated to the 
target dose according to the dosing schedule outlined in Section 7.2 . The dose titration schedule may be 
modified based on updated PK mode lling including data from the study.  
NNZ-2591 Oral Solution, 50 mg/mL, is provided as a ready-to-use strawberry-flavored liquid for oral 
administration. The IMP should not be mixed with wate r, liquid thickeners, or food for administration.  
Each day there will be two dose administrations, one in morning and one in afternoon or evening. There 
should be at least 8 hours between doses. Doses should be given on an empty stomach (2 hours after the 
previous meal or snack and 30 minutes prior to the next). Doses may be taken over a 10-minute period with a follow up of 250 mL of water.  
For all participants, the total duration of NNZ-2591 treatment will be 91 days. Dosing at the end of 
Baseline counts as Day 1 whether one or two doses are given. Dosing may not exceed 91 days including 
Day 1, and all efficacy assessments for the EOT vi sit must be completed on or before Day 91 of 
treatment. The first dose of IMP will be administered in the clin ic after all Baseline assessments are completed or, if 
the Investigator judges that it is too late in the day, on the following day. The participant should be 
monitored for at least three hours after the first dose. If the first dose is administered the day following 
Baseline, vital signs (except height) should be collect ed before the dose is administered. Day 1 of dosing 
is defined by the date when the first dose is taken. At this visit, the site will provide IMP for the caregiver 
to dispense at home. Enough IMP will be provided to c over the interval until the next in-clinic visit when 
the caregiver will be re-supplied from site.  Within the up-titration period, if a participant is deemed not to be tolerating the current dose within the 
2-week period, and they have not met any of the stopping criteria below (see Section 9.4.5 ), they can be 
down-titrated to the next lower dose in the titration schedule (See Section 7.2).The Investigator must 
attempt to increase the dose as soon as it is possible ba sed on the clinical situation. The aim is to return to 
the originally assigned dose.
 If the originally assigned dose cannot be  reached, or the participant is again 
unable to tolerate that dose, the Investigator will continue treatment on the highest dose the participant 
can tolerate. Stopping rules for the discontinuation of the administration of IMP are described in 
Section 9.4.5. Investigators are to discontinue administration of IMP if the participant meets any of the 
criteria described in Section 9.4.5. 
Note that early cessation of IMP does not necessarily  mean the participant is withdrawn from the study. 
With any early cessation, all evaluations and te sts scheduled during the study must be conducted if 
possible. 
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 74 of 112 x  
  
 
 
  
  
  
 
 
Participants who have received IMP for longer than 2 weeks and discontinue prematurely any time after 
Visit 5 should return to the investigational site for final safety and ef
ficacy assessments as scheduled for 
the EOT visit (Week 13, Visit 16) and complete the study exit form. 
Participants who discontinue from the trial prior to  receiving any treatment or who discontinue after 
having received treatment only up to Visit 5 (W eek 2 post-baseline) may be replaced.   
Participants with early treatment cessation due to SAEs must be followed-up and provided appropriate 
medical care until their signs and symptoms have remi tted or stabilized, or for the remaining study period 
(until study end), whichever comes sooner.  “Study e nd” is when all participants have completed the 
study. 
9.4.6 Concomitant Therapy 
Investigators are encouraged to follow current in ternational and hospital guidelines and current best 
medical practice for the management of participants with PTHS. Medications should be used per current 
recommendations. Concomitant medi cations permitted in the study are outlined below and are described 
in the Exclusion Criteria (Section 8.2 ).  
Medications prohibited from the study are outlined  below and in the Exclusion Criteria (Section 8.2).  
Participants should not have their existing medi cation withdrawn in order to enter the study. 
Excluded medications/treatments include:  
x Current treatment or treatment within the two we eks prior to Screening with MAO inhibitors, d-
cycloserine, oxytocin, carbetocin, tricyclic antidepressants, or bupropion. 
x Current treatment with more than 3 allowable psychotropic medications.   
o Includes medications used to treat problems with sleep onset and sleep continuity except 
melatonin. Melatonin for difficulties with sleep onset is permissible and is not included in 
the count of psychotropic medications.   
o The use of anti-epileptics for other indicatio ns such as the treatme nt of mood disorders 
counts towards the limit of permitted psychotropic medications.   
o Anti-epileptic medications used for treatment of seizures does not count towards the limit of psychotropic medications.  
x Current treatment with insulin or treatment with in the last 12 weeks prior to commencement of 
IMP. 
x Current treatment with IGF-1 or treatment with in 6 months of commencement of the IMP. 
x Current treatment with growth hormone or treatm ent within 12 months of commencement of the 
IMP. 
 

Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 75 of 112 The following medications are allowed but must be at stab le doses before the start of the study as follows:  
 
x Non-pharmacologic somatic treatment (e.g., a keto genic diet or vagal nerve stimulation): dosing 
regimen must be stable at least 4 weeks prior to Screening. If the treatm ent was discontinued, the 
discontinuation must have occurred no fewe r than 2 weeks before Screening.  
x A new behavioral, educational, or cognitive th erapy cannot be started during the period of the 
study or within 4 weeks prior to Screening. Change s to an ongoing treatment regimen that are due 
to school schedules or are otherwise seasonally related are not exclusionary as long as they are 
consistent with the typical type and pattern of be havioral treatment received by the participant.  
x Seizure medication: dosing regimen must be st able 8 weeks prior to commencing the IMP. 
Adjustments for changes in weight or age are al lowable. If the treatment was discontinued, the 
discontinuation must have occurred no fe wer than 2 weeks before Screening. 
x Psychotropics or any other medication used for a chronic illness (not including antibiotics, pain 
relievers, anti-diarrheals, and la xatives): dosing regimen must have been stable for at least 4 
weeks prior to Screening.  If the treatment w as discontinued, the discontinuation must have 
occurred no fewer than 2 weeks before the commencement of IMP. 
o This includes nutraceutical treatments a nd cannabinoids (THC and CBD) which are 
allowable but also must meet the stability conditions above. 
o The Investigator should consult with the medica l monitor if a participant is being treated 
with ocular toxic, hepatotoxic medications , nephrotoxic, or antibiotic medications.  
 
The following medications/treatments are pe rmitted and may be adjusted as needed: 
x Procedural pain control medication. 
x Laxatives and anti-diarrheals.  
Standard of care immunizations and vaccinations (including COVID-19) are allowed and are not subject to the above stability conditions.  If the Investigator is unsure if a medication is permitted, the Medical Monitor should confirm if the 
medication is allowed and will provide  written documentation to support the medication’s use, if allowed. 
Concomitant medications will be monitored in a caregiver diary fo r the approximately 4 to 6 week 
Screening period to confirm there are no changes from the time of initial screening. 
Every effort should be made to maintain stable regimens of concomitant medications and allowed non-
medicine-based therapies throughout the course of th e study, with the understanding that there will be 
some changes to non-medicinal treatment regimens that are due to school schedules or are otherwise 
seasonally related.  
Details of concomitant medications will be recorded in the participant notes and in the eCRF. 
9.5 Assessments  
9.5.1 Vital Signs  
Vital signs including weight, blood pressure (SBP and DBP in mmHg), heart rate (bpm), respiratory rate 
(rpm), and body temperature ( qC) will be assessed at the Screening visits (Visits 1 and 2) and at the 
Baseline visit (Visit 3). Height will be measured at Screening (Visit 1), Baseli ne (Visit 3) and End of 
Treatment (Week 13, Visit 16). Blood pressure (SBP  and DBP in mmHg), weight, heart rate (bpm), 
respiratory rate (rpm), and body temperature ( qC) will also be assessed at all post-enrollment study visits. 
If the first dose is administered in clinic the day af ter the Baseline visit, blood pressure (SBP and DBP in 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 77 of 112 collecting the samples to reduce contamination. 
x Complete Blood Count with Differential  (Visits 1, 3, 5, 7, 9, 11,  13, 16, 17): Hemoglobin (Hb), 
hematocrit (Hct), red cell count (RBC), white bl ood cell count (WBC), mean cell volume (MCV), 
mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), platelets (PLT), red cell 
distribution width (RDW-CV), and leukocyte count (neutrophils, ly mphocytes, monocytes, 
eosinophils, and basophils). If abnormalities are seen , additional tests may be conducted as deemed 
necessary by the Investigator and Medical Monitor and as described below in the clinical management 
plan in Sections  9.5.2.1 and  9.5.2.3 . 
x Coagulation (Visits 1, 3, 5, 7, 9, 11, 13, 16, 17): prot hrombin time test, Intern ational normalized ratio 
(INR), activated partial thromboplastin (aPTT). If  abnormalities are seen, additional tests may be 
conducted as deemed necessary by the Investigator and Medical Monitor and as described below in the 
clinical management plan in Sections 9.5.2.1  and 9.5.2.3. 
x Comprehensive Metabolic Profile (All Visits except Visit 2): amyl ase, sodium, glucose, potassium, 
blood urea nitrogen (BUN), enzymatic creatinine,  BUN/creatinine ratio, estimated glomerular 
filtration rate (eGFR), bicarbonate, chloride, total calcium, phosphorus, magnesium, bilirubin (direct 
and indirect), creatine kinase, alkaline phosphat ase (ALP), aspartate transaminase (AST), alanine 
amino transferase (ALT), gamma-glutamyl transferase (GGT), total protein, albumin, total cholesterol, and random triglycerides. If abnormalities are seen , additional tests may be conducted as deemed 
necessary by the Investigator and/or Medical Mo nitor and as described below in the clinical 
management plan in Sections  9.5.2.1 and  9.5.2.3 . 
o eGFR is calculated using the modi fied Bedside Schwartz formula: 
eGFR=(0.413*height)/creatinine mg/dL 
o This formula will be used for all participants including those who may age up to 18 years old during the study 
x Urinalysis  (All Visits except Visit 2): with microscopic analysis, glucose, bilirubi n, ketones, specific 
gravity, blood, pH, protein, albumin, urobilinogen, ni trite, and leucocyte esterase. If abnormalities are 
seen on microscopy, additional tests for culture, sens itivity and protein analysis may be conducted as 
deemed necessary by the Investigator and/or Medica l Monitor, and as described below in the clinical 
management plan in Section 9.5.2.2 .  
x Urine will also be tested at Screening, for drugs of abuse, i.e., stimulants (e.g., amphetamine, methamphetamine, methylenedioxymethamphetam ine [MDMA], cocaine), hallucinogens (e.g., 
phencyclidine), narcotics/analgesics/ opiates (e.g.,  codeine, morphine, methadone, propoxyphene), 
depressants/sedatives/hypnotics (e.g., barbiturates). 
x TSH, Free T3, Free T4 (Visits 1, 16): free triiodothyronine (T
3), free thyroxine (T 4), thyroid 
stimulating hormone (TSH). 
x Glycosylated hemoglobin (HbA1c)  (Visits 1, 16)  
x Rapid test for SARS-CoV-2 (Visits, 1, 3, 16). The site may use any test with same day results 
approved for use for children and adolescents in the US.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 83 of 112 submitted. The clinician will be queried to adjudicate  which ECG should be considered the final read and 
entered into the database. 
ECGs will be sent via secure transmission and read by a qualified central reader. The results from the 
reports from the central reader and any alert flags should be reviewed by the Investigator who will 
determine if the values are clinically significant and sign the report. Results will be assessed against the 
ECG screening criteria for QTcF at the Screening vi sit and against the QTcF stopping criteria throughout 
the study.   
Investigational Medicinal Product must be discontin ued at any time during the study in the event that a 
post-enrollment 47F) GXUDWLRQ RI  PV confirmed by a repeat continu ous ECG, or a clinically 
significant LQFUHDVH RI   PV  (confirmed by a repeat continuous ECG) compared to the average QTcF 
interval at Baseline (Visit 3, before dosing) is observed.  
9.5.9 Battery of Pitt-Hopkins Syndr ome Assessment Instruments 
The battery of PTHS specific measures will evaluate symptom change in clin ically meaningful and 
functionally impactful symptom domains for individu als with PTHS including communication, cognition, 
motor function, maladaptive behavior, adaptive behavior s, sleep, seizures, breathing and GI issues (see 
Section 6.3.2). The selection of outcome measures for this study reflects the insights from the published 
literature, and expert clinical advice. All assessments will be administered in a standardiz ed manner by trained practitioners. To the extent 
possible, all efforts should be made to maintain th e same caregiver informant or investigator rater (as 
applicable) across visits for a single  participant. If in extenuating ci rcumstances (such as severe illness), 
the caregiver is unable to complete the rating for a visit, another appropriate rater can be designated to 
complete the assessment for that visit. This should be documented in the source  and the EDC. The site 
staff should ensure the alternative rater has appropriate knowledge of the participant to complete the 
rating and is informed of the instru ctions for completing the assessments. 
Caregivers will complete most assessments via an online portal. Paper versions of assessments will also 
be used and may be made available for online versio ns in the case of difficulty accessing the electronic 
portal. These assessments should be completed the day of the visit or no earlier than the day before the 
visit. No assessments can be conduc ted until informed consent has been given by the caregiver or legally 
authorized representative. Also, training for the caregivers on all caregiver completed assessments must 
be completed before the caregiver ra ter may complete the assessments. 
Overall symptom severity and functional leve l will be assessed using the following tools: 
9.5.9.1  Clinical Global Impression of Severity (CGI-S) 
Clinical Global Impression of Severity assessments will be done at Screening (Visit 1), Baseline (Visit 3), 
Week 6 (Visit 9), EOT (Week 13, Visit 16), and Fo llow-up (Week 15, Visit 17). The Clinical Global 
Impression - Severity scale (CGI-S)
36 is a 7-point scale that requires the In vestigator to rate the severity of 
the individual's overall illness at the time of assessment , relative to the Investigat or's past experience with 
participants who have the same diagnosis.36 Considering total clinical experi ence, a participant is assessed 
on severity of illness at the time of rating: 1, normal, not  at all impaired; 2, borderline, slightly impaired; 
3, mildly impaired; 4, moderately impaired; 5, markedly impaired; 6, severely impaired or 7, among the most extremely impaired ill. Following best practice for neurodevelopmental disorders, the CGI-S will be 
evaluated using PTHS-specific scoring anchors. The c linicians will provide an overall global severity 
rating and a severity rating for each of seven domains: language/comm unication, fine motor 
functioning/self-help, social initiation/social avoida nce, challenging behavior, ambulation/gross motor, 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 84 of 112 gastrointestinal issues, and autonomic/breathing ab normalities. The clinician rater should assess the 
participant’s current state taking into consideration ob servations at the visit and symptoms within the last 
week.  To ensure that interpretation of the scoring ru bric is normalized amon g the raters, clinicians 
administering the CGI-S will be required to complete scoring calibration training. 
9.5.9.2  Clinical Global Impression of Improvement (CGI-I) 
Clinical Global Impression of Improvement assessments will be made at Visit 9 (Week 6), EOT (Week 
13, Visit 16), and Follow-up (Week 15, Visit 17). The CGI-I scale36 requires the Investigator to rate how 
much the participant’s illness has improved or worsened relative to a baseline state. A 7-point scale is 
used with the following values: 1, very much improved;  2, much improved; 3, minimally improved; 4, no 
change; 5, minimally worse; 6, much worse; 7, very  much worse.  The CGI-I will be evaluated using 
PTHS-specific scoring anchors. The clinicians will provide an overall global improvement rating and an 
improvement rating for each of seven domains: language /communication, social initiation/social 
avoidance, fine motor functioning/self-help challenging behavior, am bulation/gross motor, 
gastrointestinal issues, and autonomic/breathing abnormalities. The clinician should assess the 
participant’s current state taking into consideration ob servations at the visit and symptoms within the last 
week. The rating of change is compared with status at Baseline (Visit 3). To ensure that interpretation of 
the scoring rubric is normalized among the raters, clinicians administering the CGI-I will be required to 
complete scoring calibration training. 
9.5.9.3  Bayley Scales of Infant Development v4 (BS ID4) or Stanford-Binet Intelligence Scales 
v5 (SB5) 
The Stanford-Binet Intelligence Scales version 5 (SB5) assessment w ill be done at Screening (Visit 1) and 
EOT (Week 13, Visit 16). SB5 is validated for ages 2 to 85+ and measures both verbal and nonverbal 
intellectual and cognitive abilities through a set of 10 subtests.37 General cognitive ability is reported as a 
full-scale intellectual quotient score (FSIQ). Cognitive ability in five categories are reported in the index 
scores: fluid reasoning (FR), knowledge (KN), quantit ative reasoning (QR), visual-spatial processing 
(VS), and working memory (WM). Non-verbal (NVIQ)  and verbal intelligence quotients (VIQ) are also 
calculated. Scoring of index scores and IQ will be calculated using the z-deviation method for intellectual 
disability.38  
The Bayley Scales of Infant Development version 4 (BSID-4) is conducted fo r participants who cannot 
achieve a basal score on SB5or for whom th e SB5 is developmentally inappropriate .39 Assessment will 
be done at Screening (Visit 1) and End of Trea tment (Week 13, Visit 16). The Bayley is a norm-
referenced developmental assessme nt validated for ages 16 days to 42 months. It assesses cognitive 
ability, motor skills, and behavior and provides st andardized scores in five domains: Cognitive, 
Language, Motor, Social-Emotional, and Adaptive Beha vior. Scale scores, age equivalents and growth 
scale values (GSVs) can also be calculated fo r the scale subtests: cognition (CG), receptive 
communication (RC), expressive communication (EC), fi ne motor (FM), and gross motor (GM). Scaled 
scores and age equivalents can be calculated for the social emotional (SE) subscale. The Adaptive 
Behavior subscale will not be collected in this study. The Early Learning Composite score and scaled scores are calculated for children 42 months and you nger. Raw scores, age equivalents, and growth scale 
values are calculated for all participants. 
If the SB-5 or the Bayley had previously been admi nistered for the participant within 3 months of 
Screening, the scores from that administration ma y be used if it meets the following criteria: 1) 
assessment was administered by site personnel, or another study site; 2) the site has access to all the 
scores required to be entered in the EDC; 3) the site has permission to share the scores from the 
previously administered assessment to the study ED C. Assessments done by the school or other clinics 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 85 of 112 are not acceptable. Only scores from SB-5 and the Bayley are acceptable; cognitive scores from other 
assessments cannot be entered in the ED C in lieu of the SB-5 or the Bayley. 
9.5.9.4  MacArthur-Bates Communicative Development Inventory (MB-CDI) 
The MacArthur-Bates Communicative Development Inve ntory (MB-CDI) will be completed at Baseline 
(Visit 3) and EOT (Week 13, Vis it 16). This caregiver-completed instrument assesses language 
development through vocabulary comprehension and production, gestures, and grammar.40 Designed to 
assess early language development in infants and toddle rs, it can also be used with older, developmentally 
delayed children to assess developm ental progress in language developm ent. The MB-CDI includes three 
modules based on chronological or developmental ag e: Words and Gestures (8- to 18- months or 
developmental equivalent), Words a nd Sentences (16- to 30-months or developmental equivalent) and the 
CDI-III, an extension of the MB-CDI used with child ren 30-37 months or deve lopmental equivalent. The 
Word and Gestures module will be used for this st udy in line with the expected cognitive and language 
development of the study population. It assesses developing abilitie s in language including production of 
gestures, and vocabulary comprehe nsion and production which are repor ted as number of instances and 
percentile scores. 
9.5.9.5  ORCA (Observer-Reported Communication Ability Measure) 
The Observer-Reported Communicatio n Ability Measure (ORCA) will be completed at Baseline (Visit 3) 
and EOT (Week 13, Visit 16). This caregiver-reported  measure was originally developed and validated 
for Angelman syndrome,41 to assess the individual’s overall co mmunicative ability and was designed to 
capture communicative abilities in low-verbal and non-verb al populations, so is relevant for PTHS. It was 
developed based on feedback from a patient-focused listening session with the advocacy community and 
the Food and Drug Administration following best prac tices for measure development including concept 
elicitation interviews with caregivers and communication experts, item generation, assessment of validity 
and psychometrics, and factor analysis conf irming single overall communication ability score.41-43 The 
rating scale evaluates the caregiver’s observation of the individual’s communication ability over the past 30 days.
42 The measure consists of 84 total questions with 70 behavioral items. It assesses communication 
abilities of individuals across all modalities: gestures, AAC (augmentative and alternative 
communication) and speech so is not dependent so lely on verbal abilities. Twenty-two communication 
concepts relevant to communicative ability in PTHS are assessed with in the categories of expressive 
communication, receptive communication, and pragmatic communication rendering a total 
communication score.   
9.5.9.6   Caregiver Top 3 Concerns Rating 
The Caregiver Top 3 Concerns Rating assessment is a syndrome-specific measure of 3 signs or symptoms 
of PTHS identified by caregivers at Screening/Baseli ne as being priority concerns in which they would 
like to see improvement as a result of treatment. The assessment will be comple ted at all Screening and 
Baseline visits (Visits 1, 2, 3), as well as Week 6 (Visit 9), EOT (Visit 16), a nd Follow-up (Visit 17). 
In this assessment, concerns are id entified on an individual, per-par ticipant basis. The clinician should 
review the assessment with the caregiver at the Screen ing visit, ideally as part of the overall medical and 
clinical history. Caregivers should be encouraged , in selecting the concerns, to identify distinct, 
observable symptoms rather than broad ones. And ca regivers should be advised to consider symptoms 
that they feel are important and have an impact  on their child’s daily functioning and well-being.  
Caregivers are asked to identify 3 concerns from  among 11 clinically important symptom domains: 
Language/Communication, Social in terest/avoidance, Repetitive Beha viors, Challenging Behaviors, 
Gross motor skills, Fine motor skills, Gastrointestinal problems, Breath ing Disruptions, Sleep, Seizures, 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 86 of 112 and Self-care skills. Each individual concern identif ied should be from a different symptom domain, but 
caregivers can select any domain and choose any symptom of concern within that domain. The same three 
concerns identified at screening/baseline are carrie d forward and rated at the follow-up visits. The 
severity of each concern is scored by caregivers usin g a 10-point Likert scale or severity. The caregiver 
should give consideration to symptoms within the last two weeks.  
9.5.9.7   Aberrant Behavior Checklist-2 (ABC-2) 
The ABC-2 will be completed at all Screening and Base line visits (Visits 1, 2, 3), as well as Week 6 
(Visit 9), EOT (Week 13, Visit 16), and Follow-up (Visit 17). The Aberrant Behavior Checklist-2 (ABC-
2)44 is a caregiver-completed rating scale for assessin g problem behaviors that has been validated in a 
variety of clinical populations and been used as  an outcome measure in clinical trials of 
neurodevelopmental disorders (NDDs) across much of the lifespan.44 The rater considers the relative 
frequency of an individual’s behavior s and gives a rating of the severity of the problem it presents: 0, not 
at all a problem; 1, the behavior is a problem but slight in degree; 2, the problem is moderately serious; 3, 
the problem is severe in degree. Th e caregiver should give consideration to symptoms within the last two 
weeks.  
The ABC-2 includes 58 items providing five subscale scores: Irritability, Social Withdrawal, Stereotypic 
Behavior, Hyperactive/Noncompliance, and Inappropri ate Speech. These subscales have been shown to 
have good consistency, reliability, and validity with normative data available for specific populations 
including children with intellectual disability and ASD.45 
9.5.9.8  Behavior Problems Inventory -Short form (BPI-SF) 
The Behavior Problems Inventory Short Form (BPI-SF) will be completed at Baseline (Visit 3) and at the 
EOT (Week 13, Visit 16). The BPI-SF is a caregiver-c ompleted rating scale for assessing self-injury, 
aggressive and stereotyped behavior.46, 47 Frequency is assessed for all three types of behavior on a five-
point scale from 0 (Never), 1 (Monthly), 2 (Weekly ), 3 (Daily) and 4 (Hourly). For self-injury and 
aggression, severity is also assessed on a 3-point scale of mild, moderate, or severe. 
9.5.9.9  Caregiver Impression of Change 
The Caregiver Impression of Change assessment w ill be done at the EOT (Week 13, Visit 16). The 
Caregiver is asked to rate the change in his or her child’s overall function and well-being since the 
Baseline visit (Visit 3), and the change in specific symptom domains. Ratings are made using a 7-point 
Likert scale:1-Very much improved, 2-Much impr oved, 3-Improved, 4-Unchanged, 5-Worse, 6-Much 
worse, 7-Very much worse. For the rating of overall function, the caregiver also identifies the one symptom area or feature that has most influenced his or her rating of the child’s overall function and provides a description of symptom changes and the impa ct of the changes. The assessment of change 
should be made since the Baseline visit (Visit 3). The caregiver should assess the participant’s current state at the visit taking into consideration observatio ns at the visit and symptoms within the last week. 
9.5.9.10  Quality of Life Inventory-Disability (QI-Disability) 
The Quality of Life Inventory-Disability (QI-Disability) will be completed at Baseline (Visit 3) and EOT (Week 13, Visit 16).
48-50 The QI-Disability48 is a caregiver-report measure that assesses a child’s well-
being and quality of life over the past month. Designed to be relevant for children who have an 
intellectual disability, the QI-Disability  includes 32 questions in 6 domains: Social Interaction, Physical 
Health, Independence, Positive Em otions, Leisure and the Outdoors, and Negative Emotions. The QI-
Disability has been validated in individuals ages 5 to  18 with Rett syndrome, Downs syndrome, CDKL5 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 87 of 112 Deficiency Disorder, Cerebral Palsy, and ASD. Item s are rated on a 5-point Likert scale with a 0-100 
scaling such that the value of each rating is: never = 0, rarely =25, sometimes = 50, often = 75, and very 
often is 100. Domain scores are calculated by summ ing all the scores and dividing by the number of 
items. The total score is calculated by summing th e domain scores and dividing by the number of 
domains.  
9.5.9.11  Impact of Childhood Neurological Disab ility-Overall Quality of Life Rating (ICND) 
The Impact of Childhood Neurologic Disability Scale (I CND) will be administered at Baseline (Visit 3) 
and at End of Treatment (Week 13, Visit 16). The IC ND was developed to evaluate the impact that a 
child’s condition has on the child’s and the family’s everyday life .51 The full scale assesses the effect of 
four conditions or health problems on the child’s or the family’s life, and evaluates the child’s overall 
quality of life. In this study, only the overall qua lity of life assessment will be completed. The caregiver 
will rate overall quality of life of the participant by responding to the following: “Please rate your child’s 
overall ‘Quality of Life’ on the scale below. Choose the number which you feel is best and circle it”. The choices range from 1 (“Poor”) to 6 (“Excellent”). The caregiver should consider the child’s status in the last month including their current condition. .
 
9.5.9.12   Child Sleep Habits Questionnaire (CSHQ) 
The Child Sleep Habits Questionnaire (CSHQ) will be completed by the participant’s caregiver at all Screening and Baseline visits (Visits 1, 2, 3), as well as Week 6 (Visit 9), EO T (Week 13, Visit 16), and 
Follow-up (Visit 17). The CSHQ gath ers information on bedtime and a ssesses sleep behavior, waking 
during the night, and morning waking/daytime sleepiness
52 to assess both behavioral and medical sleep 
disorders. The CSHQ has been used across a range of NDDs including PTHS and has been used as an 
outcome measure for sleep intervention trials.53-55 It provides a total score and eight subscale scores: 
bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night awakenings, parasomnias, sleep 
disordered breathing, and daytime sleepiness. The car egiver should consider sleep behaviors within the 
last week in doing their ratings.  
9.5.9.13  Vineland Adaptive Behavior Scales-3 
The Vineland Adaptive Behavior Scales Third Editio n (Comprehensive Interview version, Vineland-3) 
will be completed at Baseline (Visit 3) and EOT (Wee k 13, Visit 16). This standardized meas ure assesses 
development and adaptive functioni ng which correspond to the domains of adaptive functioning used in 
the DSM-5: Communication, Daily Living Skills, and Socialization.56 The Vineland will be conducted as 
an interview by a trained site rater with the care giver. The measure provides an overall adaptive 
functioning score, and standardized domain scores in Daily Living Skills, Communication, Socialization 
and Motor Skills. The Vineland also has a maladaptive behavior domain which will not be completed in 
this study. V-scale scores and growth scale values (GSV) can also be calculated for the subdomains. The 
GSV scores on the Vineland have been found to be more  sensitive to change than standardized scores for 
developmentally de layed populations.57 Raw scores, standardized scores, v-scale scores, age equivalents, 
and GSV will be calculated for all participants. For par ticipants 3 to 9 years of age, Motor Skills can be 
calculated; for those older than 9 years old, sc ores will not be calculated for Motor Skills. 
9.5.9.14  GI Health Questionnaire (GIHQ) 
The Gastrointestinal Health Questionn aire (GIHQ) will be completed by the participant’s caregiver at all 
Screening and Baseline visits (Visits 1, 2, 3), as well as Week 6 (Visit 9), EO T (Week 13, Visit 16), and 
Follow-up (Visit 17). The measure was developed for use in NDDs and validated in individuals with Rett syndrome and includes GI symptoms that are relevant for PTHS.
58 The GIHQ assesses the impact of GI 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 88 of 112 issues on the individual’s life over the last two weeks.58 Items are rated on a 5-point Likert scale as 
follows: 0= it is never a problem, 1=it is almost never a problem, 2=it is sometimes a problem, 3=it is 
often a problem, 4=it is almost always a problem. A total score and 9 subtest scores are calculated with 
the 9 subtests comprising issues in three domains: Gastrointestinal symptoms, Mood/Behavior, and Parent 
Concerns.  
9.5.9.15  Modified 2-Minute Walk Test 
The modified 2-Minute Walk test (2MWT)59 is an assessment of how far an individual can walk during a 
2 minute period which assesses endurance and also has relevance for everyday functioning. The 2MWT 
will be done at Screening (Visit 1), Baseline (Visit 3) and at the EOT (Week 13, Visit 16).  For this 
assessment, the individual with PTHS walks back an d forth between two cones on a 20-meter track for 
two minutes and the total distance covered is measur ed. The modified 2MWT requires two assessors and 
one walk assistant. The walk a ssistant knows the person with PTHS well (e.g., parent, caregiver, 
therapist) and provides the necessary physical support for the person to keep his/her balance and to 
maintain the highest possible gait speed.  
9.5.10  Caregiver Diary 
A Caregiver Diary will be completed daily by the caregiv er and reviewed at all visits by the Investigator 
and by visiting nurse at remote visits. In the diary,  the participant’s caregiver will record dosing 
compliance of IMP, any changes in concomitant me dication or treatments, urine output measured by 
number of voids or wet diapers, any changes in sympto ms including changes in or al intake, sleep activity, 
seizure activity, and breathing events. The diary also sp ecifically queries changes in maladaptive behavior 
or self-injury which may suggest changes in the te ndency to self-harm. At the Screening visit, the 
clinician will review the assessment with the caregiver and assist the caregiver to define the child’s 
typical seizure types, breathing abnormalities, sleep is sues or other chronic conditions that are to be 
tracked in the diary. Any new, emergent types of se izures or breathing abnormalities, or any other new 
symptoms will also be docum ented if they occur.  
The Investigator must review the caregiver diary at or after each visit. At clinic visits, the Investigator 
will review the diary and the site will provide a new diary section to the caregiver. At remote visits, the nurse will review the diary in the home noting any potential issues in the nurse report and collect the diary to send to the Investigator along with notes from the visit. The nurse will provide the caregiver with a new 
diary section for the upcoming week. The nurse will not sign-off on the diary. The Investigator is 
responsible for reviewing the nurse notes, reviewing th e diary, signing the diary, and determining if 
anything needs to be reported as an Adverse Event.  
 
9.6 Pharmacokinetic Measurements 
Pharmacokinetic blood samples will be collected in accordance with the sampling schedule outlined in  
Table 2 for ages 7 to 17 years old and Table 3 for ages 3 to < 7 years old.  The date and actual time (hour 
and minute) that each sample is collected must be accu rately recorded. The site mu st also ensure that the 
date and time of the previous evening’s dose and the morning and evening dose on the day the sample is 
collected is accurately collected in the Caregiver Diary.  
For the Week 2, 6, and 13 data collection, the prev ious day’s PM dose should be taken in the evening as 
late as possible, preferably before bedtime. The pre-dose sample should be taken 120 minutes to 
15 minutes before the morning dose is administered. For post-dose samples, sample collection can be 
± 15 minutes of the target time and must be no closer  than 30 minutes from the previous sample (must be 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 89 of 112 at least 30 minutes from the previous sample). Th e actual collection time is recorded. The post-dose 
windows are determined from the first dose of the visit (morning dose) and all PK samples should be 
collected before the second dose (PM dose). Full de tails regarding the PK sampling collection, storage 
and shipping may be found in th e Laboratory Manual for the study. 
PK blood samples may be collected from a cannula por t or via venipuncture. Pre-prepared PK sampling 
tubes will be provided to each site within the lab vi sit kits for collection and storage of PK samples.  
Samples of whole blood will be collected, aliquoted, and will be stored at minus 20°C (or colder) no more 
than 2 hours following sample colle ction.  Samples will be shipped at designated times on dry ice and 
using temperature monitoring to the laboratory for st orage and analysis. It is essential that accurate 
records are maintained regarding the date and time ea ch PK sample is obtained, and the date and time 
each sample is placed in the 20°C freezer. The date and time of the most recent dose of IMP and most 
recent meal relative to that dose should  be recorded in the Caregiver Diary.  
Minimum requirements for a participant to be c onsidered evaluable within the PK population are 
administration of NNZ-2591 per protocol through to th e morning dose at Visit 5 (Week 2) as a minimum, 
and collection of PK samples at the specified post-dos e time point(s) through to Visit 5 (Week 2) as a 
minimum. 
 
  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 90 of 112  
10. ADVERSE EVENTS 
The Investigator and site staff are responsible for dete ction, recording and reporting of events that meet 
the criteria and definition of an AE or SAE, as de scribed below. At in-home nurse visits, the nurse will do 
a query of any changes for potential AE/SAEs and document observations from the targeted physical 
exam. The nurse will escalate any issu es related to AE/SAEs, stopping criteria, major dosing issues, or 
issues of potential safety concern to the Investigator the same day. Any changes noted will be provided to 
the Investigator who will be responsible for determining, recording, and reporting any events that qualify as AE/SAEs. 
10.1 Definition of Adverse Event 
An adverse event is any untoward medical occurrence  associated with the use of a drug in humans, 
whether or not considered drug related. An AE ca n be any unfavorable and unintended sign (e.g., an 
abnormal laboratory finding), symptom or disease tempor ally associated with the use of a drug, without 
any judgment about causality.   
AEs can include the following: 
x Exacerbation of a chronic or intermittent pre-ex isting condition including either an increase in 
frequency and/or intensity of the condition. 
x Conditions detected or diagnosed after IMP admini stration even though it may have been present 
prior to the start of the study. 
x Signs, symptoms, or the clinical sequelae of a suspected interaction. 
x Signs, symptoms, or the clinical sequelae of a suspected overdose of either IMP or a concurrent 
medication. 
SAEs are a sub-category of AEs that are defined in Section 10.2, below. AEs/SAEs are recorded and 
reported from the time of first dose of IMP until Follow-up (Visit 17). 
Planned hospital admissions for an illness or a diseas e that existed prior to administration of IMP or 
enrollment in the clinical study are generally not to  be considered AEs. Individuals who have planned 
surgical procedures that would occur during the study are to be excluded from the study (Exclusion 43).  
If the participant has a planned hospital admission (non -surgical), the Investigator should consult with the 
Medical Monitor to ensure this will not cause disrup tion of IP administration or would not qualify the 
participant for exclusion.  
Note that medical or surgical procedures are no t considered AEs (e.g., endoscopy); however, the 
condition that leads to the procedure is an AE. 
10.2 Definition of Serious Adverse Event 
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either the Investigator or Sponsor, it results in any of the following outcomes: death, a life-threatening adverse 
event, in-patient hospitalization or prolongation of existing hospitalization, a persistent or significant 
incapacity or substantial disruption of the ability  to conduct normal life functions, or a congenital 
anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropri ate medical judgment, they may 
jeopardize the participant and may require medical or surgical intervention to prevent the outcomes listed 
in this definition. 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 92 of 112 All AEs occurring after administration of the dose of  IMP and on or before the final visit must be 
reported. These are referred to as treatment emergent adverse events (TEAEs).  All AEs must be recorded 
irrespective of whether they are considered drug related. 
At each visit/assessment in the period defined above, AEs will be evaluated by the Investigator and 
recorded. 
Any AEs already documented at a previous assessment and designated as ongoing, should be reviewed at 
subsequent visits. If these have r esolved, this should be documented. 
10.7 Recording of AEs and SAEs 
When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation  
(e.g., hospital progress notes, laboratory, and diagnostics reports) relevant to the event. The Investigator 
should then record all relevant info rmation regarding an AE/SAE on the eCRF. It is not acceptable for the 
Investigator to send photocopies of the participant’s medical records to the Sponsor in lieu of completion 
of the appropriate AE/SAE eCRF pages. However, there may be instances when the Sponsor requests 
copies of medical records for certain cases. In this instance, all partic ipant identifiers will be removed on 
copies of the medical records prior to submission to the Sponsor. 
The Investigator will attempt to establish a diagnosis  of the event based on signs, symptoms, and/or other 
clinical information. In such ca ses, the diagnosis should be docu mented as the AE/SAE and not the 
individual signs/symptoms.  
10.8 Evaluating AEs and SAEs 
10.8.1  Assessment of Intensity 
The Investigator will make an assessment of intens ity for each AE and SAE reported during the study.  
The assessment will be based on the Investigator’s clinical judgment. The intensity of each AE and SAE 
recorded in the eCRF should be assigned to  one of the following three categories: 
Mild:   
An event that is easily tolerated by the participant,  causing minimal discomfort  and not interfering with 
everyday activities. 
Moderate:   
An event that is sufficiently discomforting to interfere with normal everyday activities. 
Severe:   
An event that prevents normal everyday activities. An AE that is assessed as severe should not be confus ed with an SAE. Severity is a category utilized for 
rating the intensity of an event; and both AEs and SAEs  can be assessed as severe. An event is defined as 
‘serious’ when it meets one of the pre-de fined outcomes as described in Section 10.2 Definition of 
Serious Adverse Event.  
10.8.2  Assessment of Causality 
The Investigator is obligated to assess the relations hip between IMP and the occurrence of each AE/SAE. 
The Investigator will use clinical judgment to determ ine the relationship. Alternative causes such as 
natural history of the underlying dise ases, concomitant therapy, other risk factors, and the temporal 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 93 of 112 relationship of the event to the IMP will be considered and investigated. The Investigator will also consult 
the Investigator’s Brochure in the dete rmination of his/her assessment.   
All AEs will be assessed by the Principal Investigator or qualified and authorized delegate as to whether 
there is a ‘reasonable possibility that the drug caused the event’ and on that basis be classified as either 
‘related’ or ‘not related’. 
There may be situations when a SAE has occurred and the Investigator has minimal information to 
include in the initial report to the Sponsor. However, it is very important that the Investigator always 
make an assessment of causality for every event prior to transmission of the SAE form to the Sponsor.  
The Investigator may change his/her opinion of causa lity in light of follow-up information, amending the 
SAE form accordingly.   
10.8.3  Follow-up of AEs and SAEs 
After the initial AE/SAE report, the Investigator is required to proactively fo llow each participant and 
provide further information to the Sponsor on the participant’s condition. 
All AEs and SAEs documented at a previous visit/contact and are designated as ongoing, will be 
reviewed at subsequent visits/contacts. 
All AEs will be followed until resolution, until the condition stabilizes, or until 30 days after the 
participant’s Visit 17 Follow Up, whichever occurs fi rst. At which time, the appropriate AE/SAE eCRF 
page(s) will be updated. SAEs and renal AEs that are ongoing at the Follow-u p visit (Visit 17) will be 
followed until resolution, stabilization of participant condition, or study end, whichever occurs first. In 
such cases, follow-up Serious Advers e Event Report (SAER)  forms will 
be completed at the Follow-up visit (Visit 17) as well as completed upon resolution, stabilization, or study 
end, whichever occurs first. “Study end” is when all participants have completed the study. 
The Investigator will ensure that follow-up includes any supplemental in vestigations as may be indicated 
to elucidate the nature and/or causality of the AE or  SAE. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care professionals. 
The Sponsor may request that the Investigator pe rform or arrange for the conduct of supplemental 
measurements and/or evaluations to elucidate as fully as possible the nature and/or causality of the AE or 
SAE.  The Investigator is obligated to assist. If a participant dies during the study or during a recognized 
follow-up period, the Sponsor will be provided with a copy of the death certificate and any post-mortem 
findings, including histopathology. 
New or updated information will be recorded on the originally completed SAE  
with all changes signed and da ted by the Investigator.  The update d SAE form should be re-sent to 
the Sponsor within the time frames outlined below in Section 10.8 Prompt Reporting of the SAEs to the 
Sponsor.  
Any clinical adverse event that is serious (as define d above in Section 10.2)  
  occurring during the course 
of the study, irrespective of the treatment received by the participant, must be reported to the Sponsor and 
Sponsor’s agent within 24 hrs (or sooner if possible) of the Investigator or designee becoming aware of the situation. 

Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 97 of 112 Pharmacokinetic (PK) Population 
 
The PK population will include all par ticipants enrolled in this study wh o receive the IMP through to the 
morning dose of Visit 5 (Week 2) as a minimum, and who undergo PK sample collection at the specified 
post-dose time point(s) through to Visit 5 as a minimum.  
 
11.1 Sample Size Determination 
Sample sizes were estimated for this open-label st udy using within-participant change as the measure of 
improvement. Given the limited data from interventional trials in these pa tient populations, and that this is 
the first clinical study for NNZ-2591 IMP in this population, treatment change  estimates were based on 
Clinical Global Impression Scale of Improvement (CG I-I) data from completed clinical trials in other 
rare, neurodevelopmental disorders.  
Based on the information provided in Glaze et al. 2019 (Double-blind, randomiz ed, placebo-controlled 
study of trofinetide in pediatric Rett syndrome), the standard deviation of the CG I-I is approximately 0.7 
at a single timepoint.1 For a sample size of 10 pa rticipants, a two-sided significance level of 0.05, and a 
Wilcoxon signed-rank test, the study will be able to det ect a difference of 0.87 units of change in the CGI-
I at a power of 0.90. For a power of 0.80, 0.85, and 0.90, the detectable difference would be 0.75, 0.80, 
and 0.87 or larger, respectively. The effect size for a power of 0.80, 0.85, and 0.90 is 1.07, 1.14, and 1.24, 
respectively. If the observed standard deviation is la rger, the detectable differences would also be larger. 
For example, if the standard deviation is 1.5, the de tectable difference for a power of 0.80, 0.85, and 0.90 
is 1.61, 1.71, and 1.86 or larger, respectively. Fo r a sample size of 20 participants, a two-sided 
significance level of 0.05, and a Wilc oxon signed-rank test, the study will be able to detect a difference of 
0.55 units of change in the CGI-I at a power of 0.90. For a power of 0.80, 0.85, and 0.90, the detectable 
difference would be 0.48, 0.51, and 0.55 or larger, respectively. 
11.2 Safety Analyses 
Safety analyses will be conducted on the Safety Popula tion and based on the safety endpoints listed in 
Section 6.3.1. Adverse events and other safety data will be  summarized as frequencies and percentages, 
described in terms of severity and potential attribu tion. Objective safety asse ssments will be summarized 
over time on study; shift tables at time points of interest may be generated. The safety analysis details will be specified in the Statistical Analysis Plan (SAP). 
11.3 Efficacy Analysis 
Efficacy will be assessed by looking at within-participant changes from the Baseline period to the EOT 
using the efficacy endpoints listed in Section 6.3.2. 
 The participant’s baseline characteristics and symptom severity will be established based on assessments collected during the 4 to 6 week Sc reening/Baseline period. Baseline valu es will be based on the average 
values of visits 1, 2, and 3 for assessments collected at more than one visit. A Wilcoxon signed rank test 
will be used to test for improvement and an exact significance level will be computed.  
 Potentially influential factors will be considered and addressed with a linear regression model. This model may include covariates such as age, sex, nonverb al NVIQ or NVIQ equivalent, genotype, history of 
regression (yes/no), ASD diagnosis (yes/no) with no more than two covariates included in any model. 
Descriptive statistics and corresponding graphics will be used to present the results. The safety and 
efficacy analysis details will be specified in the SAP. 
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 98 of 112 11.4 Pharmacokinetic Analysis 
The PK analysis will be based on the endpoints listed in Section 6.3.1 . Pharmacokinetic (PK) measures 
will be collected from all participants at Visits 5 (Week 2), 9 (Week 6), and 16 (Week 13, EOT).   
NNZ-2591 PK concentrations will be listed by particip ant and time point for each dose level with actual 
time they were acquired. The concentrations will be summarized by time, dose level, and age group. For 
the concentrations measured at trough points dose re lationship will be examin ed statistically with age 
group and/or body weight of participant as covariate. 
Overall exposure parameters for NNZ-2591 such as C max and AUC tau may be derived by sparse non-
compartmental analysis (NCA). Ad ditionally, PK concentrations of NNZ-2591 measured in pediatric 
participants will be used to refine population PK model developed from adult NNZ-2591 PK data and 
extrapolated to pediatric population. After refineme nt, complete profiles for each participant will be 
simulated using range of variability of model paramete rs and individual covariate effects. A standard 
NCA approach will be used for simulated profiles to calculate parameters C max, AUC tau, etc. for 
characterization of NNZ-2591 exposure in pediatric participants. 
The PK analysis details will be specified in the PK SAP. 
11.5 Biomarkers and Microbiome 
Blood and stool samples will be collected for an explor atory analysis of biomarkers and gut microbiome. 
The analysis will be detailed in a separate analys is plan but will not include DNA sequencing. Samples 
will be collected at Screening (Visit 1) and Baseline (Visit 3, before dosing) and at the EOT visit (Week 
13, Visit 16), or upon early termination. 
12. STUDY DRUG MANAGEMENT  
12.0 Identity of Investigational Medicinal Product 
NNZ-2591 Oral Solution, 50 mg/mL IMP is supplied in 250 mL white PET PP28 neck bottles with white 
28 mm child resistant and tamper evident caps. NNZ- 2591 Oral Solution, 50 mg/mL IMP is manufactured 
under GMP by Quay Pharmaceuticals Ltd. (28 Parkway, Deeside Ind Park, Flintshire CH5 2NS). 
• Name of Drug: NNZ-2591 
• INN: None 
• Chemical Name: Cyclo-L- *O\F\Oဨဨ$OO\O 3UROLQH F*ဨဨ$OO\O3  
• Molecular formula: C 10H14N2O2 (net) 
• Chemical Abstracts Service (CAS) Registration Number: 847952-38-9 
• Physical appearance of formulation: Clear, pink to  red, non-viscous, free from visible particulates 
• Odor and flavor of formulation:  Sweet strawberry odor and flavor 
NNZ-2591 Oral Solution, 50 mg/mL IMP is provided as a ready-to-use strawberry-flavored liquid for oral 
administration. The IMP is stored at 15-25°C in white 250 mL PET PP28 neck bottles with white 28 mm 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 99 of 112 child resistant and tamper evident white caps. The primary and secondary label text and design complies 
with U.S. FDA regulatory requirements and local codes of good manufacturing practice for medicinal 
products, as applicable, and will in clude the batch number, the manufac turing date of the IMP and the 
retest date of the product. 
12.1 Management of Clinical Supplies 
Investigational Medicinal Product, along with the di spensing cups and syringes,  will be supplied to the 
site Pharmacist. The site Pharmacy contact is re sponsible for IMP management including receipt and 
correct storage/handling, dose calculation an d IMP preparation, IMP accountability, and proper 
destruction of unused IMP and empty bottles. Full deta ils regarding the preparation, storage, resupply, 
and stability of NNZ-2591 Oral Solution, 50 mg/mL may be found in the Pharmacy Manual. 
NNZ-2591 Oral Solution, 50 mg/mL bottles will be shippe d at 15-25°C and should be stored at 15-25°C 
(temperature monitored), according to the procedures outlined in the Pharmacy Manual. NNZ-2591 Oral 
Solution, 50 mg/mL must be mainta ined in a secure area with access restricted to designated study 
personnel. Investigational site personnel should notify the Study Monitor immediately if IMP bottles are 
damaged or if temperature excursions occur during storage. 
12.1.0  Drug Accountability 
The Investigator or designees must maintain an invent ory record of the IMP admi nistered to ensure that 
the investigational drug has been stored as per specifications and administered only to enrolled participants, in accordance with this protocol. Refer to the Pharmacy Manual for accountability 
procedures. 
The IMP is to be prescribed only by the site Princi pal Investigator or named sub-Investigators and may 
not be used for any purpose other than  that outlined in this protocol.  
The Pharmacist and clinical team (as applicable) have  been delegated responsibility from the Principal 
Investigator to maintain accurate records detailing the quantity of IMP kits received, dispensed, used, 
destroyed, or returned. During the study, the fo llowing must be noted in the Treatment Log: 
x The study number and initials of the par ticipant to whom IMP is dispensed. 
x The date(s) and quantity of IMP dispensed. 
Study participants will be instructed to return em pty dosing bottles and any unused medication to the 
clinic. These returns will be accounted for in the clinic and the bottles and accountability form will be 
provided to the Pharmacy for reconciliati on with dispensing and IP tracking logs.  
At the end of the study, all unused IMP will be returned  to the Sponsor’s designee or destroyed by the site 
according to the Sponsor’s instructions, once it has b een inventoried and the Study Monitor has reviewed 
the drug accountability records.  
12.2 Overdose 
Participants should not exceed the maximum daily doses or take any two doses within an 8-hour interval. 
If an administered dose is spat out, regurgitated, or  vomited, the dose should NOT be re-administered, and 
this should be documented in the dosing diary or the source documents for the in-clinic dose. There is no 
specific antidote to NNZ-2591 IMP.  In the event of an overdose, appropriate supportive measures should 
be employed as clinically indicated and the Medi cal Monitor must be in formed immediately.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 100 of 112 13. QUALITY ASSURANCE A ND DATA MANAGEMENT 
13.1 Data Quality Assurance 
The following measures will be implemented to en sure accuracy, consistency, completeness, and 
reliability of data: 
x Investigator discussions 
x Site initiation training 
x Early site visits following enrollment 
x Routine site management 
x Ongoing site communication and training 
x Periodic site monitoring  
x Data management quality control checks 
x Statistical quality control checks 
x Continuous data acquisition and cleaning 
x Internal review of data 
x Quality control check of the final study report 
13.2 Case Report Forms 
This study will utilize web-based eCRFs developed thr ough a 21CFR Part 11 compliant platform. Prior to 
the initiation of the trial, each site will be contacted as to computer availability, hardware specifications, 
security infrastructure, internet connec tivity, etc., to evaluate their capacity to use this type of data capture 
system. The Investigator and site personnel will be responsible for co mpleting the eCRFs or ensuring the 
completion of forms to be completed by the caregivers and entered into the EDC via the secure portal for 
caregiver raters. The Investigator is responsible fo r the accuracy and reliability of all the information 
recorded on the eCRFs. All information requested on the eCRFs needs to be supplied, including 
participant identification data, visit date(s), assessme nt values, etc., and any omission or discrepancy will 
require explanation. All information on eCRFs must be traceable to source documentation at the site. 
During periodic monitoring visits, the site will ma ke their computer and/or high-speed Internet access 
available to the Study Monitor so that he or sh e may verify the data entries with the source 
documentation.  
13.3 Monitoring 
A Sponsor’s Study Monitor will visit each site in accord ance with the Clinical Monitoring Plan set forth 
for this trial as well as maintain regular telephone  and written communication. Monitoring visits will be 
conducted by representatives of the Sponsor according to the ICH Guideline for Good Clinical Practice 
(GCP), and applicable regional regulations and guidelines. The Investigator will agree to the monitors making periodic site visits during the study. The timing of 
these visits will be agreed by the moni tors and the study site personnel.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 101 of 112 Monitoring will be on an ongoing basis by site. Th e assessments are to be captured on a specialized 
device/computer (e.g., 12-lead ECG) or in an online format or paper format (e.g ., clinician and caregiver 
rating scales) and are to be obtained at the time of testing. It is imperative that the Investigator ensures 
that all tests are completed at each session, according to the participant’s capability. Data collected at the 
site will be entered into the eCRFs in centrali zed, password protected EDC system. Checking for 
completeness and rationality will be undertaken via th e EDC at a central location. If discrepancies are 
noted, the site monitor will be al erted and site follow-up undertaken in order that problems may be 
resolved immediately. This may require retraining of investigators on the testing process and the importance of competing the testing correctly.  
13.4 Auditing 
The Sponsor (or Sponsor nominee) may conduct period ic audits of the study processes including, but not 
limited to, the clinical site and the bioanalytical labo ratory. The Investigator must authorize access and 
make available all study related documents to au thorized Sponsor’s representatives and regulatory 
authorities. 
The scope of a clinical site audit may include but will not be limited to drug accountability, regulatory 
documentation, the informed consent process, a nd comparison of eCRFs against source data. The 
Investigator agrees to cooperate with audits conduc ted at a reasonable time and in a reasonable manner. 
Regulatory agencies involved with the study may also a udit the Investigator during or after the study. The 
Investigator should contact the Spons or immediately if this occurs. 
13.5 Source Documents 
The Investigator will, within reason, prepare and maintain adequate and accurate source documents (e.g., medical records, ECGs, raw data collection forms, and electronic source documents) to record all 
observations and other pertinent data  for each participant enrolled into  the study. The Investigator will 
allow Sponsor representatives and authorized regulatory authorities to access documents pertaining to the study. 
13.6 Protocol Deviations 
This study will be conducted as described in this prot ocol, except during an emergency situation in which 
the protection, safety and well-being of the participant requires immediate intervention, based on the judgment of the Investigator (or appropriately qualified designee). In the event of a significant deviation from the protocol, the Investigator or designee must contact the Sponsor or the Medical Monitor at the earliest possible time by telephone. This will allow an  early joint decision regarding the participant’s 
continuation in the study. The Investigator will document the outcome of the discussion in the source 
documents and the Sponsor likewise will retain a docum entary record of the d ecision. The Sponsor will 
reserve the right to recommend susp ension or discontinued involvement of  the site if excessive protocol 
deviations occur. 
13.7 Records Retention 
The Investigator must maintain essential study documents (protocol a nd amendments, completed eCRFs, 
source documentation, signed informed consent form s, relevant correspondence and approvals, and all 
other supporting documentation) until at least 2 years after the last approval of a marketing application in 
an ICH region and until there are no pe nding or contemplated marketing a pplications in an ICH region or 
at least 2 years have elapsed since the formal discontinuation of clinical development of the 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 102 of 112 Investigational Medicinal Product. These documents s hould be retained for a longer period if required by 
the applicable regulatory requirements or the clinic al site’s procedures. Participant identification codes 
(participant names and corresponding study numbers) wi ll be retained for this same time period and 
stored separately.  Custody of the records may be tran sferred to another responsible party, acceptable to 
the Sponsor, which agrees to abide by the retention policies. Written notice of transfer must be submitted 
to the Sponsor. The Investigator must contact the Sponsors prior to disposing of any study records. 
Records retention will follow the Data Protectio n requirements in the participating country.
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 103 of 112 14. ETHICS 
14.1 Informed Consent 
Written informed consent will be obtained from a pa rent or legally authorized representative of the 
participant before any study-related procedures are performed. The Investigator has an ethical and legal 
responsibility to ensure the parent or legally au thorized representative of each participant being 
considered for inclusion in the study is given a full explanation of the study. The Investigator or designee 
shall inform the parent or legally authorized repres entative of each participant in writing of all aspects 
pertaining to the participant’s participation in th e study including (but not limited to) aims, methods, 
anticipated benefits, and potential risks. The particip ant’s parent or legally authorized representative will 
have the opportunity to inquire about details of the study and to decide whether to participate.  
A participant’s parent or legally authorized representa tive should understand that they are free to refuse to 
allow the participant to participate in, and are free to  withdraw the participant from, the study at any time 
without prejudice or loss of medical care to which they are otherwise entitled. They have the ability to 
withdraw the participant from the study at any time, for any reason. 
The parent or legally authorized representative of each participant must personally sign and date a study-
specific informed consent form on behalf of the pa rticipant to be a participant in the study. The 
participant’s caregiver who will complete the study assessments must also provide written informed 
consent regarding their participation in the study prior to participating in any study procedures. The form 
must be countersigned by the site Investigator w ho conducted the informed consent discussion (or an 
authorized designee). Authorized designees will be  defined according to local center and ethics 
requirements. Their authorization will be documented on a written informed consent form, which, 
together with this protocol, will be approved by an IRB.  
A separate consent for potential re-use of leftover Biomarker and PK samples in later research, including 
potential genetic research, is optional. 
Each informed consent will include the elements required by U.S. 21 CFR 50 and ICH E6, Section 4.8. 
The Investigator agrees to obtain approval from the IRB and Sponsor for any written informed consent 
form proposed for use in the study prior to submission to the IRB. 
Each parent or legally authorized representative w ho provides written informed consent for a participant 
to participate in the study (by signing and dating of the form) will be given a copy of the signed informed 
consent form, and assent form if the minor is capable of signing an assent form or providing oral consent 
as required by local IRB regulations. The originals will be kept in the center’s regulatory file and a second 
copy filed in the participant’s medica l record as permitted by the institu tion. The Investigator will inform 
participants and the parent or legally authorized repr esentative of new information that may be relevant to 
the participant’s willingness to contin ue participation in the study according to local ethics requirements. 
It is important to obtain complete follow-up for all pa rticipants enrolled. Every attempt should be made to 
undertake all protocol specified assessments and complete the eCRF except for those participants who 
specifically withdraw consent for release of such information. 
14.2 Institutional Review Board Approval 
The Investigator will not begin the study until the protocol and informed consent form have been approved by the local Institutional Review Board (IRB) or  specifically for the site by the central IRB as 
dictated by institutional requirements . Any amendments to the protocol must also be approved in writing 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 104 of 112 by the Sponsor, and the local IRB or central IRB for the site prior to implementation by the Investigator, 
except where necessary to eliminate an im mediate hazard to study participants. 
Written IRB approval of the protocol and Study In formation Forms/Informed Consent Forms will be 
typed on the Institutional letterhead and will refer to the Study Information Forms/Informed Consent 
Forms and to the study by title and protocol number gi ven by Neuren Pharmaceuticals on the protocol.  A 
copy of the signed and dated letter of  approval will be provided to Neuren Pharmaceuticals prior to study 
commencement. Any written information and/or advert isements to be used for volunteer recruitment will 
be approved by the IRB prior to use. 
All IRB correspondence including progress reports will be retained on file at the clinical site.  
14.3 Additional Protections for Minors 
The age-related inclusion criterion for the study protocol will allow enrollment of participants aged 3 to 
17 years. Participants aged younger th an 18 are considered to be minors and, collectively, they constitute 
a vulnerable population. Additional regulations are in  place for their protection (45 CFR Part 46 Subpart 
D).  Normally, minors cannot legally provide consent to participation in research on their own behalf.  
Consent must be provided by one or both parents, or a legally authorized representative, while the minor 
provides “assent” for participation. Assent is the minor’s affirmative agreemen t to participate in the 
research.   Since this protocol involves greater than minimal risk but presents the prospect of direct benefit to all 
participants enrolled, consent shall be obtained from a guardian or at least one parent in accordance with 
local IRB requirements. Minors will be given the opportun ity to assent to participation if and when they 
are considered capable of doing so by the Investigator and per local IRB requirements. 
 
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 105 of 112 15. STUDY MANAGEMENT 
The Sponsor will appoint the project management team, and an independent DS MC. Project management 
may be delegated to a Contract Research Orga nization who will be overseen by the Sponsor. 
15.1 Principal Investigators 
A Principal Investigator will be appointed at each part icipating site to personally  supervise all aspects of 
the conduct of the study at their site.  
15.2 Data Safety Monitoring Committee 
An independent DSMC will monitor the progress of the tr ial and ensure that the safety of trial participants 
is not compromised. The DSMC will pr ovide independent affirmation that no safety or tolerability issues 
are arising in the study through their on-going review  of the study data. Specifically, the DSMC will 
review the clinical safety data prior to any individua l dose titration and prior to initiation of subsequent 
age groups. The DSMC will review safety data and make an adjudication on: 1) the ability for any 
individual participant to escalate to the next higher dos e and 2) the ability for enrollment to begin in the 
younger age groups (Groups 2 and 3).  
The DSMC will minimally consist of a clinical chair, ot her physicians experienced in clinical trials with 
pediatric expertise (but not participating in this st udy), and a pediatric cardiologist. The DSMC Charter 
details the DSMC processes, duties,  and responsibilities as well as the study-wide stopping criteria. 
15.3 Publications 
All publication rights are delineated in the Clinical Study Agreement and/or other separate agreements 
with the Investigator and/or Institution, as applic able. ICMJE uniform requirements will be respected, 
with regard to the composition, authorship and su bmission of manuscripts derived from this study. A 
publication committee will be composed that will include the principal investigators (or appropriate 
designees) as well as Sponsor representatives.   
 
 
  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 106 of 112 16. REFERENCES 
1. Glaze DG, Neul JL, Kaufmann WE, et al. Double- blind, randomized, placebo-controlled study of 
trofinetide in pediatric Rett syndrome. Neurology . Apr 16 2019;92(16):e1912-e1925. 
doi:10.1212/WNL.0000000000007316 
2. Sweetser DA, Elsharkawi I, Yonker L, et al. Pitt-Hopkins Syndrome . Gene Reviews. University of 
Washington, Seattle; 2018. 
3. Zollino M, Zweier C, Van Balkom ID, et al. Diagnosis and management in Pitt-Hopkins syndrome: 
First international consensus statement. Clin Genet . 2019;95(4):462-478.  
4. Marangi G, Sollino M. Pitt-Hopkins Syndrome and Differential Diagnosis: A Molecular and Clinical 
Challenge. J Pediatr Genet . 2015;4(3):168-176.  
5. Fierro JAA, Avina DAH. Pitt-Hopkins syndrom e: Mental retardation, psychomotor and 
developmental delays with facial dysmorphism. J Pediatr Genet . 2014;3:141-145.  
6. Whalen S, Heron D, Gaillon T, et al. Novel comprehensive diagnostic strategy in Pitt-Hopkins 
syndrome: clinical score and further deli neation of the TCF4 mutational spectrum. Hum Mutat. 
2012;33:64-72.  
7. Marangi G, Ricciardi S, Orteschi D, et al. Th e Pitt-Hopkins syndrome: report of 16 new patients and 
clinical diagnostic criteria. Am J Med Genet A . 2011;155A:1536-1545.  
8. Goodspeed K, Newsom C, Morris MA, Powell C, Evans P, Golla S. Pitt-Hopkins Syndrome: A 
Review of Current Literature, Clinical  Approach, and 23-Patient Case Series. J Child Neurol . 
2018;33(3):233-244.  
9. De Winter CF, Baas M, Bijlsma EK, van Heuke lingen J, Routledge S, Hennekam RC. Phenotype and 
natural history in 101 individuals  with Pitt-Hopkins syndrome through an Internet questionnaire 
system. Orphanet J Rare Dis. 2016;11:37.  
10. Rosenfeld JA, Leppig K, Ballif BC, et al. Genot ype–phenotype analysis of TCF4 mutations causing 
Pitt-Hopkins syndrome shows increased se izure activity with missense mutations. Genet Med . 
2009;11(11):797-805.  
11. Giurgea I, et al. TCF4 dele tions in Pitt-Hopkins Syndrome. Hum Mutat. 2008;29:E242-51.  
12. Van Balkom ID, Vuijk PJ, Fr anssens M, Hoek HW, Hennekam RC . Development, cognition, and 
behaviour in Pitt-Hopkins syndrome. Dev Med Child Neurol . 2012;54(10):925-931.  
13. Watkins A, Bissell S, Moss J, et al. Behaviour al and psychological characteristics in Pitt-Hopkins 
syndrome: a comparison with Angelman  and Cornelia de Lange syndromes. J Neurodev Disord . 2019 
Oct 5 2019;11(1):24.  
14. Sweatt JD. Pitt–Hopkins Syndrom e: intellectual disability due to loss of TCF4-regulated gene 
transcription. Exp Mol Med . 2013;45:e21.  
15. Zweier C, Sticht H, Bijlsma EK, et al. Furthe r delineation of Pitt-Hopkins  syndrome: phenotypic and 
genotypic description of 16 novel patients. J Med Genet . 2008;45(11):738-744. 
doi:doi:10.1136/jmg.2008.060129 
16. Ghosh PS, Friedman NR, Ghosh D. Pitt-Hopkins  syndrome in a boy with Charcot Marie Tooth 
disease type 1A: a rare co-occur rence of 2 genetic disorders. J Child Neurol . 2012;27(12):1602-1606.  
17. Taddeucci G, Bonuccelli A, Mantellassi I, Orsini  A, Tarantino E. Pitt-Hopkins syndrome: report of a 
case with a TCF4 gene mutation. Ital J Pediatr . 2010 Feb 2 2010;36:12.  
18. de Pontual L, Mathieu Y, Golzio C, et al. Mutati onal, functional, and expression studies of the TCF4 
gene in Pitt-Hopkins Syndrome. Hum Mutat. 200 9;30(4):669-6 7 6.  
19. Peippo M, Ignatius J. Pitt-Hopkins Syndrome. Mol Syndromol . 2011;2(3-5):171-180.  
20. Huisman S, Winter C, Menke L. Diagnosis and Management in Pitt-Hopkins Syndrome: First 
International Consensus Statement. Clin Genet . 2019;95:462-467.  
21. Amiel J, Rio M, de Pontual L, et al. Mutations  in TCF4, encoding a class I basic helix-loop-helix 
transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy 
associated with autonomic dysfunction. Am J Hum Genet . 2007;80(5):988-993.  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 107 of 112 22. Zweier C, Peippo MM, Hoyer J, et al. Haploi nsufficiency of TCF4 causes syndromal mental 
retardation with intermittent hyperv entilation (Pitt-Hopkins syndrome). Am J Hum Genet. 
2007;80(5):994-1001.  
23. Brzozka MM, Radyushkin K, Wichert SP, Ehrenreich H, Rossner MJ. C ognitive and Sensorimotor 
Gating Impairments in Transgenic Mice Overexpres sing the Schizophrenia Susceptibility Gene Tcf4 
in the Brain. Biol Psychiatry . 2010;68(1):33-40.  
24. Sepp M, Kanike K, Eesmaa A, Urb M, Timmus k T. Functional diversity of human basic helix-loop-
helix transcription factor TCF4 isoforms genera ted by alternative 5’ exon usage and splicing. PLoS 
One. 2011;6(7):e22138.  
25. Navarrete K, Pedroso I, De Jong S, et al. TCF4  (e2-2; ITF2): A schizophrenia-associated gene with 
pleiotropic effects on human disease. Am J Med Genet B Neuropsychiatr Genet . 2012;162B(1):1-16.  
26. Pscherer A, Dorflinger U, Kirfel J, et al. 7KH KHOL[ဨORRSဨKHOL[ WUDQVFULSWLRQ IDFWRU 6()ဨ UHJXODWHV WKH
activity of a novel initiator element in the promot er of the human somatostatin receptor II gene. 
EMBO J . 1996;15(23):6680-6690.  
27. Brockschmidt A, Todt U, Ryu S, et al. Severe mental retardation with breathing abnormalities (Pitt-
Hopkins syndrome) is caused by haploinsufficiency of the neuronal bHLH transcription factor TCF4. 
Hum Mol Genet . 2007;16(12):1488-1494.  
28. Blake DJ, Forrest M, Chapman RM, et al. TC F4, schizophrenia, and Pitt-Hopkins Syndrome. 
Schizophr Bull . 2010;36(3):443-447.  
29. Crux S, Herms J, Dorostkar MM. Tcf4 regulates dendritic spine density and morphology in the adult 
brain. PloS ONE . 2018;13(6):e0199359.  
30. Forrest MP, Waite AJ, Martin-Rendon E, Blake DJ. Knockdown of human TCF4 affects multiple 
signaling pathways involved in cell survival, epith elial to mesenchymal transition and neuronal 
differentiation. PLoS ONE. 2013;8(8):e73169.  
31. Guan J, Gluckman P, Yang P, et al. Cyclic glycine-proline regulates IGF-1 homeostasis by altering 
the binding of IGFBP-3 to IGF-1. Sci Rep . 2014;4:4388.  
32. Glaze DG, Neul JL, Percy A, et al. A double-blind, randomized, placebo-controlled clinical study of 
trofinetide in the treatment of Rett syndrome. Pediatr Neurol . 2017;76:37-46.  
33. Kuo DZ, Houtrow AJ. Recognition and management of medical complexity. Pediatrics . 2016;138(6) 
34. The Pitt Hopkins Research Foundation. The Pitt-Hopkins Syndrome Community Voice Report. 2019. 35. Grodberg D, Weinger PM, Halpern D, et al . The Autism Mental Status Exam: Sensitivity and 
Specificity Using DSM-5 Criteria for Autism Spect rum Disorder in Verbally Fluent Adults. J Autism 
Dev Disord . 2014;44:609–614.  
36. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology—
Revised . U.S. Department of Health, Education, and We lfare; Public Health Service, Alcohol; Drug 
Abuse, and Mental Health Administration; National Institute of Mental Health; Psychopharmacology Research Branch; Division of Extramural Resea rch Programs.; 1976:218-222. vol. DHEW Publ No 
ADM 76–338. 
37. Roid GH. Stanford-Binet Intelligence Scales, Fifth Edition . Riverside Publishing; 2003. 
38. Sansone SM, Schneider A, Bickel E, Berry- Kravis E, Prescott C, Hessl D. Improving IQ 
measurement in intellectual disabilities us ing true deviation fr om population norms. J Neurodev 
Disord . 2014;6(1):16.  
39. Bayley N, Aylward GP. Bayley Scales of Infant and Toddler Development (4th edition) . NCS 
Pearson; 201 9.
 
40. Fenson L, Marchman V, Thal D, Dale P, Reznick JS, Bates E. MacArthur-Bates Communicative 
Development Inventories: User’s Gu ide and Technical Manual. Second Edition.  Paul Brookes 
Publishing; 2019. 
41. Lucas N, McFatrich M, Zigler CK, et al. Designi ng measures of communicati on ability in individuals 
with Angelman syndrome [abstract/poster]. Quality of Life Research . 2019;28:S117-S117. 
doi:https://doi.org/10. 1007/s11136-019-02257-y  
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 108 of 112 42. Zigler C, Lin L, Lucas N, et al. The Observ er-Reported Communication Ability (ORCA) measure: 
Validation for use in clinical trials for indivi duals with Angelman syndrome [abstract/poster]. Quality 
of Life Research. 2020;29(1):S181-S182.  
43. Panagoulias J, Berent A., et al. Regulatory development of a novel outcome measure to assess 
communication ability in children with Angelman syndrome [abstract/poster]. Quality of Life 
Research . 2020;29(1):S61-S62.  
44. Aman MG, Singh NN. Aberrant Behavior Checklist - 2nd Edition (ABC-2 ). Slosson Education 
Publications, Inc. 
45. Aman MG. Annotated Biography on the Aberrant  Behavior Checklist (ABC). Columbus, OH: The 
Ohio State University; 2012. 
46. Rojahn J, Rowe EW, Sharber AC, et al. The Be havior Problems Inventory-Short Form (BPI-S) for 
individuals with intellectual disabilities I: devel opment and provisional c linical reference data. J 
Intellect Disabil Res . 2012;56:527-545.  
47. Rojahn J, Rowe EW, Sharber AC, et al. The Be havior Problems Inventory-Short Form (BPI-S) for 
individuals with intellectual di sabilities II: Reliability and Validity. J Intellect Disabil Res . 
2012;56:546-565.  
48. Downs J, Jacoby P, Leonard H, et al. The Quality of Life Inventory-Disability (QI-Disability) Qual 
Life Res . 2019;28(3):783-794. doi:10.1007/s11136-018-2057-3 
49. Epstein A, Williams K, Reddihough D, et al. C ontent validation of the Quality of Life Inventory-
Disability. Child Care Health Dev . 2019;45:654-659.  
50. Jacoby P, Epstein A, Kim R, et al. Reliability of the Quality of Life Inventory-Disability (QI-
Disability) measure in children with intellectual disability. J Dev Behav Pediatr . 2020;41(7):534-539. 
doi:10.1097/DBP.0000000000000815 
51. Camfield C, Breau L, Camfield P. Assessing the impact of pediatric epilepsy and concomitant 
behavioral, cognitive, and physical/neurologic disab ility: Impact of Childhood Neurologic Disability 
Scale. Dev Med Child Neurol . 2003;45:152-159.  
52. Owens JA, Spirito A, McGuinn M. The children’s sleep habits questionnaire (CSHQ): psychometric 
properties of a survey instrument for school-aged children. Sleep . Dec 15 2000;23(8):1043-1051.  
53. Richdale A, Baker E. Sleep in individuals with an intellectual or developmental disability. Curr Dev 
Disord Rep . 2014;1:74-85.  
54. Malow BA, Adkins KW, Reynolds A, et al. Parent-based sleep education for children with autism 
spectrum disorders. J Autism Dev Disord . 2014;44(1):216-228.  
55. Gandhi A, Zhou D, Alaimo J, et al. Compos ite Sleep Problems Observed Across Smith–Magenis 
Syndrome, MBD5-Associated Neurodevelopmental Disorder, Pitt–Hopkins Syndrome, and ASD. J 
Autism Dev Disord . 2021;51:1852-1865.  
56. Sparrow SS, Cicchetti DV, Saulnier CA. Vinela nd Adaptive Behavior Scales, Third Edition. San 
Antonio, TX: Pearson; 2016. 
57. Farmer CA, Kaat AJ, Thurm A, et al. Person ability  scores as an alternative to norm-referenced scores 
as outcome measures in studies of neurodevelopmental disorders. Am J Intellect Disabil . Nov 1 
2020;125(6):475-480. doi:10.1352/1944-7558-125.6.475. PMID: 33211814 
58. Motil KJ, Khan N, Coon JL, et al. Gastrointes tinal Health Questionnaire for Rett Syndrome: Tool 
Development. J Pediatr Gastroenterol Nutr . Mar 1 2021;72(3):354-360. 
doi:10.1097/MPG.0000000000002951 
59. Stahlhut M, Downs J, Leonard H, Bisgaard AM, Nordmark EA-K. Build ing the repertoire of 
measures of walking in Rett syndrome. Disabil Rehabil . 2017;39(19):19 26-1 931. 
doi:10.1080/09638288.2016.1212280 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 109 of 112  
Appendix A.  Allometric scaling to det ermine phase 2 exposures 
 
To determine the appropriate dose for pediatric participants, the Sponsor performed allometric scaling as 
discussed with the FDA in the Pre-IND Meeting. The findings from the allometric scaling analysis are 
summarized below . 
The allometric scaling analysis wa s performed using the pharmacokinetic data from the Phase 1 study of 
NNZ-2591 in healthy adults (PK Report Neu-2591-HV-001) . The purpose of the allometric scaling is to 
predict exposure in younger and lighter participan ts based on observed exposures in adult healthy 
volunteers at steady-state from the completed clinical study (Neu-2591-HV-001) for the dose of 12 mg/kg (cohort M2). 
1. Methods for the Allometric Scaling  
Steady-state PK parameters were used in the modeling. Median and percentiles were estimated for steady-
state clearance CLss/F on Day 7 morning dose for the adult participants in the Neu-2591-HV-001 study to 
be used as input for allometric scaling. Median and 5th and 95th percentiles for the AUC
tau at steady-state 
for the adult participants were us ed as a target exposure in childre n for comparison of the results.  
Fi value was already accounted for in the appa rent steady state clearance CLss/F. The WT centered  value for 
the study was median body weight for the participan ts in M1 and M2 cohorts of the study Neu-2591-HV-
001 was equal to 73 kg.  Median CLss/F derived for steady-state expo sure for Day 7 morning dose was used as CL
TV. Since the 
CLss/F was derived for body weight adjusted do ses and hence was estimated as L/hr/kg for the 
simulations, the value was multiplied by the median weight of 73 kg to represent true value for the 
population of adult participants in the study Neu-2591-HV-001.  
For simulation of exposure for children 3-17 (the pl anned age group for the Phase 2 study), the Centers 
for Disease Control and Prevention (CDC) Growth Individual charts with 3rd and 97th percentiles (3rd, 
10th, 25th, 50th, 75th, 90th, and 97th) were dow nloaded from the CDC.gov website. The body weights 
for boys and girls from 36.5 months (3 years) to 17 y ears old (203.5 months) inclusive were combined for 
the input to Phoenix WinNonLin as a csv file. The file contained columns for 3rd, 5th, 10th, 25th, 50th, 
75th, 90th, 95th, and 97th percentiles for each month of age and gender individually. Column with gender was added for the combined dataset. Age groupings for the allometric sca ling analysis were Group 1 (3 to 
< 6), Group 2 (6 to <12), and 12-17. 
The equation for allometric scaling was implemented in the Data Wizard function of Phoenix WinNonLin 
using weight for children of different age, gender, and percentile as direct input.  
Doses were varied in the range from 11 to 20 mg/kg for final estimate with 1 mg/kg increments. The dose 
levels 11, 12, 13, 14, … 20 mg/kg were used to calcu late the related exposures for different body weight 
values and compare the resulting AUC
tau values with adult results.  
Additionally, a 17.5-mg/kg dose was evaluated for th e lowest body weights. Preliminary evaluation of 
suitable doses was done starting from 3 mg/kg dose le vels. The parameters derived for this allometric 
scaling were AUC tau at steady state to compare with adult exposures. 
 
Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0
Confidential Neu-2591-PTHS-001 October 30, 2023
Page 110 of 1122. Allometric Scaling Results
Non-compartmental parameters for NNZ-2591 in adult participan ts from the study Neu-2591-HV-001 
were evaluated for dose proportionality of exposure after single, first doses and multiple steady-state 
doses of NNZ-2591 in healthy adult participants . Evaluation of dose proportionality supported the 
application of the published allometric scaling formula to steady state exposure parameter AUC tauto be 
matched to adult exposures using body weight nor malized dose in mg/kg and apparent steady state 
clearance in healthy adult participants. The predicted exposures (steady-state AUC tau) were calculated 
from adult median CLss/F, estimated for morning and evening 12 mg/kg doses on Day 7 in the study 
Neu-2591-HV-001, for different dose values and body weights from CDC Growth Chart. 
The findings showed that overall the predicted pedi atric exposures were lower than adult exposures for 
the 12mg/kg dose for comparisons of exposure for di fferent dose values versus weight. Combining the 
dose into 3 age groups resulted in significant overlap of body weight and differen ces in the dose projected 
to match adult exposure for 12 mg/kg dose within th e group. Hence, body weight -based dosing instead of 
age-related dosing was originally proposed for the do se selection for children. The combined plots of 
AUC tauvs weight are as shown in Figure A1. 
Figure A2 Predicted AUC tauof NNZ-2591 for different dose values vs weight all ages combined
Source: Figure 5 in Report Allometric scaling for PK of NNZ-2591 for Pediatric Population with PMS, AS, and 
PTHS 

Neuren Pharmaceuticals Ltd. Clinic al Trial Protocol Version 3.0 
Confidential Neu-2591-PTHS-001 October 30, 2023 
 
  Page 112 of 112 a Source: Neu-2591-HV-001 study adpc dataset, Phoeni x 8.3 output for Project file Allometric 
Neuren.phxproj; CDC Growth chart reported in Figure 5 in the Allometric Scaling Report. 
b Report 1901515 and Report SOW6, 0621-20173NB_w_ in-life_Bioanalytical and Pharmacokinetic 
Report_Mouse Whole Blood_NNZ-2591_27Aug2020  
This more conservative approach , which maintains the planned st aggered enrollment of age groups, 
ensures that each nominal dose is ad ministered to the older group before  that dose is administered in the 
younger pediatric participants. As such the younger age groups receive only nominal doses that have been 
administered to the older group instead of exposur e-equivalent weight-based doses at higher nominal 
doses. Given that it was estimated from allometric scaling that exposures would be lower for children < 
70 kg at 12 mg/kg than for adults at 12 mg/kg, dosing all children at a maximum of 12 mg/kg will not put 
them at risk of exposures higher than that experienced by healthy adults. So, this approach to the dosing maintains the balance between risk and benefit for this first Phase 2 study in the Angelman syndrome 
population.  
 